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Abstract 
The use of covalent irreversible binding inhibitors is an established concept for drug 
development. Usually the discovery of new irreversible kinase inhibitors occurs serendipitously 
showing that efficient rational approaches for the rapid discovery of new drugs are needed. 
Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of 
the FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia 
(AML). A virtual screening library was designed to target the highly conserved Cys828 residue 
preceding the DFG motif by modification of reported reversible inhibitors with chemically 
reactive groups. Prospective covalent docking allowed the identification of two lead series, 
resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible 
inhibitors compared to the corresponding reversible scaffolds. Lead compound 4b (BSc5371) 
displays superior cytotoxicity in FLT3-dependent cell lines to compounds in recent clinical trials 
and overcomes drug-resistant mutations.  
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Introduction  
Acute myeloid leukemia (AML) is a malignant neoplasia affecting hematopoietic progenitor 
cells. These cells fail to differentiate into functional blood cells of the myeloid path 
(erythrocytes, neutrophils and thrombocytes), while ongoing cell proliferation leads to the 
accumulation of myeloblasts in the bone marrow.1 The most common pathogenic mutations 
occur on the gene encoding for FMS-like tyrosine kinase 3 (FLT3). Length mutations in this 
gene through internal tandem duplications (ITD) in the juxtamembrane domain occur in about 
25% of patients and lead to ligand-independent auto-phosphorylation and downstream 
signaling.2 Point mutations in the FLT3 kinase domain (e.g. D835Y) occur in 10% of patients 
and destabilize the inactive kinase conformation leading to higher kinase activity.3 In 2017 the 
multitargeted kinase inhibitor Midostaurin (PKC412) was approved by the US Food and Drug 
Administration (FDA) in combination with chemotherapy for the treatment of de novo FLT3-
mutated AML showing a 22% reduction of risk of death.4 Minimal residual disease after 
treatment with tyrosine kinase inhibitors (TKIs) like sorafenib and quizartinib can lead to relapse 
and is often associated with resistance-conferring point mutations in an FLT3-ITD allele.2 As 
emergence of drug-resistant mutations is a common liability of targeted therapies, new agents 
with distinct properties are needed. The use of irreversibly binding TKIs has several advantages 
over classical reversible inhibitors such as an increased target residence time, altered selectivity, 
as well as more durable responses than their reversibly binding counterparts while idiosyncratic 
toxicity and sustained off-target effects are additional risks.5 They act by the formation of a 
covalent bond between an amino acid with a nucleophilic side chain such as cysteine and a 
chemically reactive electrophilic group (CRG) connected to a specific ligand. Bond formation 
usually takes place after a strong non-covalent complex has formed that positions the CRG in 
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close vicinity to the target nucleophile. Upon covalent bond formation, irreversible reactions rule 
out ligand dissociation leading to non-equilibrium inhibition kinetics. Thus, the enzyme function 
can be restored by de novo synthesis only.  
So long, four TKIs are approved by the FDA for the treatment of certain malignancies, 
afatinib,6 neratinib,7 osimertinib,8 and ibrutinib,9 act by irreversibly inhibiting the EGF-receptor 
family and Bruton´s tyrosine kinase, respectively. 
The natural product hypothemycin is a resorcylic acid lactone that irreversibly inhibits 18 
kinases, including FLT3.10 The cis-enone motif is attacked by a cysteine directly preceding the 
DFG motif at the start of the activation loop (Cys828 in FLT3). These so-called “group 4” 
cysteines are the most conserved in the human kinome occurring in 48 of about 500 kinases.11 A 
crystal structure analysis of hypothemycin and ERK2 confirms covalent binding in the DFG-in 
conformation.12 Despite the advantages of irreversible inhibitors, only few drug development 
efforts have focused on targeting this group of cysteines. Examples include benzoquinone-
substituted quinazolines targeting VEGFR213 and analogues or ring-opened derivatives of 
resorcylic acid lactones targeting FLT3, showing only micromolar cellular activity.14 
Recently, discovery of covalent binding inhibitors was advanced by the development of 
molecular modelling algorithms that allow covalent docking.15 In 2015, our group introduced the 
covalent docking tool DOCKTITE16 as a freely available script package for the Molecular 
Operating Environment.17 In this method a CRG is tagged by a pre- or user-defined trans-
formation, that is then attached to a selected covalent attachment point of the receptor. During 
docking the nucleophilic residue is detached from the receptor but fixed by a tight 
pharmacophore. This strategy allows highly customizable virtual screening strategies while all 
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docking steps can be monitored and controlled. Consequently, DOCKTITE has been 
successfully used for the development of covalent inhibitors for the cysteine proteases 
rhodesain,18-19 cruzain18 and falcipain20 as well as for the plasmodium proteasome.21 Despite the 
recent progress described, only one case study identifying covalent kinase inhibitors in silico has 
been reported so far. London et al. successfully used the DOCKovalent tool to identify covalent 
reversible inhibitors of the kinases RSK2 and JAK322 as well as irreversible MKK7 inhibitors, 
that were published while this study was under revision.23 However, the scope of covalent 
docking methodology has to be enlarged, as only cyano acrylamides and acrylamides were 
evaluated and hit identification profited by available protein-ligand structures with the modified 
target cysteine (RSK2) or numerous cocrystal structures with related hinge binders (JAK3, 
MKK7), respectively. 
Because of the impressive clinical benefits of irreversible inhibitors and the vulnerability of 
FLT3 treatment to resistance we sought to rationally design and evaluate irreversible FLT3 
inhibitors.  
In the following, we present a strategy that allows the identification of irreversible FLT3 
inhibitors with superior cytotoxicity to inhibitors in clinical trials that can overcome resistance-
conferring mutations of FLT3. 
Results and Discussion 
Rational Design of Irreversible FLT3 Inhibitors. A major drawback of FLT3 inhibitors in 
recent clinical trials was the acquisition of point mutations within the ATP-binding site thus we 
decided to target FLT3 in its catalytically active DFG-in conformation. Within the ATP-binding 
site FLT3 possesses three targetable cysteine residues. Two of them, Cys694 (gatekeeper + 3) 
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and Cys695 (gatekeeper + 4), are part of the hinge region while Cys828 is preceding the 
conserved DFG-motif. Kinase inhibitors usually gain potency by forming alternating hydrogen 
bond donor/acceptor interactions with the hinge backbone atoms. Therefore modification of 
known hinge binding motifs are promising starting points to target the neighboring Cys828 
residue. Additionally, exposure of Cys828 to the surface of the ATP binding pocket allows 
variation of the trajectory by which a CRG is recognized and a covalent bond can be formed. 
However, no crystal structure of FLT3 in the active conformation has been reported, so we 
designed a homology model of the active FLT3 conformation using c-KIT (pdb 1PKG) as a 
template (Figure S1-S3).24 
 
Figure 1. (a) Virtual screening and filter strategy for the in silico discovery of irreversible FLT3 
inhibitors; (b, c) Structure of CRGs and pose distribution among scaffolds. HA: α-halo 
acetamide, AC: acrylamide, VS: vinyl sulfonamide and PA: propargyl amide (d) Rational design 
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and docking hits of the bisaminopyrimidine scaffold 3 and (e) the indolinone inhibitor scaffold 6 
(gk = gatekeeper residue). 
 
c-KIT is the most closely related kinase to FLT3 with a sequence similarity of 79% and a 
sequence identity of 64% and consequently numerous shared potent inhibitors.25 To validate the 
homology model, we docked hypothemycin covalently to Cys828 of FLT3. Rigid body 
alignment of the top-scored conformation docked into FLT3 with the conformation obtained 
from the co-crystallized structure in ERK2 gave a r.m.s. deviation (RMSD) of 1.34 Å, while the 
top-scored redocked pose in ERK2 showed a RMSD of 1.08 Å (Figure S4). To identify potent 
reversible inhibitors as starting points for reactive modifications and subsequent covalent 
docking, the publicly accessible BindingDB Database was manually searched for FLT3 
inhibitors with distinct hinge binding motifs (Figure 1a, 1752 entries as of Jan. 2015).26 Typical 
inhibitors that were excluded contain bisarylurea motifs such as sorafenib, quizartinib and 
ponatinib that are designed to occupy the hydrophobic pocket II and thus bind to the inactive 
DFG-out conformation.2 We found a set of 13 different hinge binding scaffolds (Figure S5) and 
identified a plausible reversible binding pose for each scaffold (Figure S6 – S18). Those 
scaffolds form mono- (5 scaffolds), bi- (6 scaffolds) or tridentate (2 scaffolds) alternating 
hydrogen bond donor/acceptor interactions to the gatekeeper+1 (Glu692) and +3 residue 
(Cys694) that are comparable to hinge binding observed from crystal structures of related 
scaffolds.27 We selected four chemically and sterically distinct CRGs (Figure 1b) to be attached 
to the non-covalent docked structure. The acrylamide (AC), vinyl sulfonamide (VS) and 
propargyl amide (PA) groups span approximately 5 Å, while the α-halo acetamide (HA) warhead 
spans only 3.8 Å (Figure S19). We concluded, that CRG-substitution of aromatic ring carbons 
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within 5 Å to the Cys828 sulfur may enable covalent binding (Figure S6F to S18F), while 
favorable conformations were selected by covalent docking. Subsequently, we identified 32 
attachment points among the selected scaffolds leading to a targeted virtual library of 128 
compounds (Table S1). Since addition of nucleophiles to the propargyl amide can lead to E- or 
Z- substituted alkenes, addition to the covalent attachment point prior to pharmacophore docking 
gave 160 docking input structures. 
Virtual Screening and Filter Strategy. Covalent docking was performed using the 
pharmacophore placement method. The pharmacophore features of the 13 scaffolds were defined 
by the aryl, donor and acceptor groups forming hinge interactions and complemented with a tight 
pharmacophore at the target cysteine (Figure S6E to S18E). However, the pharmacophore feature 
of the nucleophilic sulfur atom in Cys828 was less stringent (d = 3.0 Å) allowing different 
rotamers. The initial docking gave 831 poses (Table S2, Figure S20) that were filtered for 
Glu692 and Cys694 backbone hydrogen bond donor acceptor interactions (404 poses left) and 
subsequently rescored using the DSX scoring function28 while only the top 5 poses of every 
ligand were retained (319 poses left). We then calculated the ligand efficiency based on the 
London dG score and set a cutoff at -0.5 kcal/mol/heavy atom to limit the search to highly 
efficient inhibitors (102 poses left, Figure 1c, Table S3 – S5). From the reversible scaffolds, 5 
scaffolds retain more than 10 hits of the corresponding reactive inhibitors (73% of total hits). On 
average, 32% of the initial docking hits in this group ranging from 13% (bisaminopyrimidine, 
scaffold 3) to 67% (indolinone, scaffold 6) are retained by the filter strategy. The hit distribution 
varies widely among the CRGs. With 45% of total hits vinyl sulfonamides are the most abundant 
group, followed by the α-halo acetamides (29%), acrylamides (16%) and propargyl amides 
(10%). 
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Characterization of Reversible Binding Fragments. As the potency of irreversible binding 
inhibitors is based on a moderate affinity between target and ligand in a reversible equilibrium 
prior to inactivation, we sought to evaluate the potency and structure-activity relationship of the 
selected reversible hits to further increase efficiency and the success rate of prospective 
irreversible inhibitor design. As the rational design starts from reported reversible ligands, 
synthetic procedures used to prepare reversible compounds 1a to 1g were based on earlier work 
(see experimental section). Among the initial series of reversible inhibitors (1a to 1e), 
bisaminopyrimidine 1a is the most cytotoxic compound (89% cell death, 10 µM, Table 1) and 
strongest inhibitor of FLT3wt. The indolinone 1b shows a comparable inhibition for FLT3wt and 
FLT3(D835Y). Imidazopyridine 1c and quinazoline 1d are less potent inhibitors of 
FLT3(D835Y) while azaindole 1e shows only weak inhibition of FLT3wt. However, all of the 
compounds of the initial series show only low cytotoxic activity in FLT3-ITD mutant MV4-11 
cells. To increase reversible binding affinity, we applied small changes to the most promising 
inhibitors 1a and 1b that are compatible with the initial, reversible docking poses leaving the 
attachment points for the CRGs unchanged (Figure 1d, e; S21a, b). Exchange of the phenyl ring 
in 1b with a 2-pyrrole (1g) constrains a planar conformation of the ligand by formation of an 
intramolecular hydrogen bond. The 5-methyl group connected to the pyrazolyl amine 1a was 
changed to a cyclopropyl ring (1f) that has also been reported to efficiently target FLT3.29 These 
small modifications massively increase the cytotoxicity of both scaffolds as well as inhibition of 
FLT3 and FLT3(D835Y) kinase activity making these fragments an efficient starting point for 
the development of irreversible inhibitors. The same modifications were applied to the poses 
obtained from the initial covalent docking and subsequent energy-minimization leaves the poses 
largely unchanged (Figure S21c – j).   
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Table 1. Inhibition of FLT3wt; FLT3(D835Y) and MV4-11 cell viability treated with reversible 
binding fragments. a Eurofins KinaseProfiler, b ADP-Glo Assay. 
Structure Compound 
IC50 
(MV4-11) 
/ nM 
Relative Inhibition (cTKI = 1 µM) / % 
FLT3wt a FLT3 (D835Y)b 
 
1a > 1.000 nM 82 15 
 
1b > 1.000 nM 60 45 
 
1c > 1.000 nM 76 8 
 
1d > 1.000 nM 26 25 
 
1e > 1.000 nM 25 83 
 
1f 230±53 98 88 
 
1g 380±21 97 86 
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Characterization of Indolinone-based Irreversible Inhibitors. A total of nine inhibitors based 
on the reversible indolinone hit 1g were synthesized (Table 2). In addition to the CRG-
substituted derivatives we synthesized the analogous unreactive inhibitors to assess the effect of 
the amide or sulfonamide linking group on reversible binding affinity. To evaluate the hit rate of 
the screening strategy, we also synthesized the inhibitors that were not identified as a hit during 
virtual screening. The 5-substituted vinyl sulfonamide 2i was the most potent inhibitor of this 
series showing a 5-fold in-crease in inhibition of MV4-11 cell viability compared to the initial 
fragment as well as the highest inhibition of kinase activity in FLT3(D835Y) and FLT3(ITD) in 
this series. Importantly, the unreactive ethyl sulfonamide 2h shows a massive decrease in 
inhibition of cell viability and kinase activity with decreased inhibition in FLT3(D835Y) and 
FLT3(ITD) suggesting that potency arises from covalent bond formation as both compounds are 
able to adopt the same reversible conformations. The vinyl sulfonamide warhead gave the 
highest number of hits in silico with the top virtual ligand-efficiency (LEV) at rank 6 of the 102 
hits (LEV = -0.55) and further poses on ranks 16, 22, 41 and 67. The propargyl amide 2g as well 
as acrylamide 2f shows a massive loss of cytotoxic activity compared to the initial hit similar to 
the unreactive propione amide 2e and low inhibition in kinase assays.  
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Table 2. Inhibition of cell viability of MV4-11 cells and FLT3-mutant kinase activity by the 
indolinone fragment 1g and the corresponding 5-substituted indolinones 2a – i with chemically 
reactive electrophilic groups and the analogous unreactive groups. 
 
  
 
R = 
Compound 
IC50 
(MV4-11) 
/ nM 
Relative Inhibition / % 
FLT3(D835Y) 
FLT3(ITD) 
c = 0.1 µM c = 0.1 µM c = 1 µM 
- H 1g 380 ± 21 40 86 61 
 
2a > 1.000 47 90 33 
 
2b 845 ± 20 57 92 51 
 
2c 72 ± 8 53 87 61 
 
2d 653 ± 200 48 92 21 
 
2e > 1.000 15 81 44 
 
2f > 1.000 29 79 25 
 
2g 709 ± 50 5 58 55 
 
2h > 1.000 13 72 9 
 
2i 67 ± 8 77 96 93 
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Thus, covalent inhibition is not favorable for acrylamide 2f though it had been identified in a 
single pose during virtual screening (rank 1, LEV =  -0.61) obtaining a similar conformation as 
2i. The α-halo acetamides show comparable inhibition of kinase activity in FLT3(D835Y) with 
the unsubstituted acetamide while a slight preference for the α-chloro acetamide was found 
inhibiting FLT3(ITD). While the reversible acetamide-substituted indolinone fragment 2a shows 
no inhibition of MV4-11 cell viability, the α-fluoro- (2b) and α-bromo-substituted (2d) 
acetamides are less active than the initial screening hit 1g. The α-chloro acetamide 2c shows 
similar cytotoxicity as the vinyl sulfonamide 2i. Having established the structure-activity 
relationship of indolinone-based irreversible inhibitors we reanalyzed the results from covalent 
docking to explain disagreements between predicted and confirmed hits. 
A possible cause for the false-positive hit acrylamide 2f might be the negligence of the covalent 
bond formation as only the reversible fragment and the final covalent complex are modeled 
during covalent docking. The energy profile of the dihedral angle between the C-C-N plane of 
the aromatic amine and the C-N-S plane of the reactive group in the top-scored pose of the active 
vinyl sulfonamide 2i shows that the energy is close to a local minimum while the dihedral angle 
is only changed by 3° (56° to 59°) after energy-minimization of the unbound ligand (Figure 2a, 
S22). The position of the targeted distal carbon atom is slightly shifted by 0.72 Å giving an 
overall RMSD of 0.49 Å. In contrast, the position of the distal carbon atom in the top-scored 
docking pose of the inactive acrylamide 2f is changed by 2.24 Å while the dihedral angle is 
changed by 39° (overall RMSD 0.89 Å) explaining that the identified hit could not be confirmed 
experimentally as the modeled conformation of the CRG is unfavorable (Figure 2b). 
Furthermore, conformational search of unbound ligands 2f and 2i shows that the acrylamide  
warhead is oriented in-plane of the indolinone ring, while the vinyl sulfonamide retains multiple 
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conformations out-of-plane enabling induced fit to the ATP binding site and vicinity to Cys828 
(Figure S23). We further assume that the initial pharmacophore distance of 1.5 Å might be too 
stringent to allow binding of all warheads, as the α-halo acetamide series was a false negative hit. 
Consequently, redocking of the α-halo acetamide derivatives 2b to 2d was performed using 2 Å 
ligand pharmacophores. This adjustment led to numerous plausible docking poses and thus 
showed to be predictive for covalent inhibition by α-halo acetamides (Figure S24).  
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Characterization of Bisaminopyrimidine-based Irreversible Inhibitors. Similar to the 
indolinone scaffold, we synthesized 14 inhibitors of the 3- and 4-substituted bisaminopyrimidine 
scaffold including derivatives with all four types of CRG to include structures predicted as hits 
and predicted negatives as well as the corresponding reversible substitutions (Table 3). Similarly, 
the vinyl sulfonamide derivatives 3m and 3n of the initial fragment 1f show massively increased 
inhibition of MV4-11 cell viability while the corresponding reversible structures 3k and 3l show 
similar cytotoxicity as the reversible fragment 1f. Inhibition of FLT3 activity shows a 
comparable increase in inhibition for the reactive derivatives towards FLT3(D835Y) and 
FLT3(ITD). Interestingly, 3m shows lower inhibition of FLT3(ITD) but 25-fold increased 
cytotoxicity in MV4-11 cells suggesting synergistic off-target effects. The 3-methyl derivatives 
corresponding to 3m (2 hits, rank 51, 96) and 3n (3 hits, rank 17, 54, 83) have been identified 
during virtual screening and redocking of 3m and 3n gave similar conformations (Figure S21k – 
n). These results show that the screening protocol chosen allows predictive hit finding for the 
bisaminopyrimidine scaffold as well. 
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Table 3. Inhibition of cell viability of MV4-11 cells and FLT3-mutant kinase activity by the 
bisaminopyrimidine fragment 1f and the corresponding 3- and 4-substituted inhibitors 3a – n 
with chemically reactive electrophilic groups or the analogous unreactive groups. 
 
 
R= 
Compound Substitution 
IC50 
(MV4-11) 
/ nM 
Relative Inhibition / % 
FLT3(D835Y) FLT3(ITD) 
c = 0.1 µM c = 1 µM c = 0.1 µM 
-H 1f - 230 ± 53 52 88 27 
 
3a 3 > 1.000 36 85 54 
3b 4 > 1.000 45 86 82 
 
3c 3 175 ± 2 33 90 74 
3d 4 141 ± 13 39 93 74 
 
3e 3 > 1.000 37 90 66 
3f 4 > 1.000 34 80 22 
 
3g 3 787 ± 100 22 81 50 
3h 4 521 ± 65 29 84 59 
 
3i 3 > 1.000 38 58 2 
3j 4 > 1.000 45 54 17 
 
3k 3 489 ± 17 32 92 59 
3l 4 129 ± 16 72 96 86 
 
3m 3 2.3 ± 0.1 47 90 73 
3n 4 58 ± 16 86 95 99 
 
 
 
 
 
The acrylamide substitution shows no benefit in cytotoxicity compared to the reversible 
fragment 1f while the corresponding reversible inhibitors 3e and 3f are almost inactive. During 
virtual screening the acrylamides have been identified as low-ranked compounds only (3g: rank 
99 of 102, 3h: rank 49, 101). The 3- and 4- substituted propargylamides 3i and 3j are the least 
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active inhibitors of this series displaying only neglectable MV4-11 cytotoxicity. Although the 
propargyl amide 3j yielded no poses during screening, 3i was identified (rank 10, 45). Reversible 
acetamide-substitution of the initial screening hit leads to a loss of cytotoxicity in 3- (3a) as well 
as 4-position (3b) while the α-chloro substitutions in 3c and 3d leads to a slightly increased 
cytotoxicity compared to fragment 1f  suggesting a covalent mode of action. However, inhibition 
of FLT3(D835Y) and FLT3(ITD) was comparable to reversible acetamides 3a and 3b, a trend 
already observed with the indolinone α-chloro-acetamide 2c, suggesting that kinase screening 
alone would under-estimate the overall potential of this CRG. In summary, the screening strategy 
presented gave a hit rate of 73% based on the number of predicted poses (16 correct-positive, 6 
false-positive, Figure S25) where all of the vinyl sulfonamide derivatives (3 hits, 10 poses) are 
validated. 
Design of 2nd Generation Indolinone Inhibitors. As the design of covalent binding inhibitors 
was based on fragmentation of larger lead compounds, we aimed to increase FLT3 inhibition and 
cytotoxicity by merging the most active irreversible fragments with the parent scaffold. The 
bisaminopyrimidine scaffold is less suitable for this purpose as the pyrazolyl amine motif may 
lead to promiscuous kinase inhibitors.30 
Exemplary, we tested activity of the reversible inhibitors 1f and 1g on the far-distant kinases 
GSK3α and GSK3β yet containing the DFG-1 Cys residue, showing potent inhibition for 1f 
(74% and 76% at 1 µM) but only insignificant inhibition by 1g (12% and -6% at 1 µM). 
Furthermore, inhibition of cell viability is about 10-fold higher for the meta substituted vinyl 
sulfonamide 3m than for the isomer 3n while inhibition of FLT3 kinase activity shows the 
opposite trend suggesting that cytotoxicity may arise from synergistic effects by off-target 
inhibition. Furthermore, 3m and 3n are potently cytotoxic towards FLT3wt THP1 cells and 
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FLT3-negative Jurkat cells (Table 4). Additionally, ligand efficiency in MV4-11 cells is higher 
for the indolinone derivatives 2c (-0.34) and 2i (-0.33) than for the bisaminopyrimidine 
derivatives 3m (-0.29) and 3n (-0.26). Furthermore, the top-scored pose of redocked fragments 
2c and 2i resemble the orientation of sunitinib in cocrystal structures, where the 3-carbon of 
pyrrole is exposed to the solvent site of the ATP binding pocket (Figure S26). 
Irreversible indolinone scaffolds 2c and 2i thus were merged with the parent inhibitor sunitinib 
by addition of a 2- and 4-methyl group to the pyrrole ring as well as a 3-carboxamide-linked 
ethylene diethylamine group to give the hybrid structures 4a and 4b (Figure 2c). Synthesis was 
performed similar to procedures described before (SI chapter 2h). Redocking in FLT3 DFG-in 
was performed using a 2 Å pharmacophore of the indolinone hydrogen bond donor, acceptor and 
aryl feature. The top-scored binding poses of 4a and 4b show comparable binding modes as 
fragments 2c and 2i and sunitinib (Figure 2d, e; S27, S28). The conformation of the solvent-
exposed diethylamine group is highly flexible (Figure S29). Receptor-free energy minimization 
of the ligand shows a distance of the vinyl Cβ atom of 1.12 Å to its position in the docked pose 
while the energy plot as a function of the dihedral angle of the sulfonamide is close to its 
minimum (Figure S30). 
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Figure 2. Comparison of the docked (green) and energy-minimized structure (blue) of (a) the 
active vinyl sulfonamide 2i and (b) the inactive acrylamide 2f. (c) Structure of 2nd-generation 
indolinone inhibitors. (d) Top-scored covalent docking pose of 4a and (e) 4b.  
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Table 4. Inhibition of cell viability in FLT3-mutated (MV4-11), FLT3wt (THP1) and FLT3-
negative (Jurkat) cells after 72 h treatment. Inhibition of purified kinase activity is determined at 
100 µM ATP and 30 min pre-incubation of kinase and inhibitor using the ADP Glo assay. a Half-
life towards 100-fold excess of reduced glutathione and 10 µM inhibitor as determined by 
HPLC. n.d. = not determined. 
 
 
 
 
Introduction of the 4-methyl group close to Cys694 changed the position of the sulfonamide 
group, slightly forcing a strong hydrogen bond donor-acceptor interaction with Lys644. 
Molecular dynamics simulation of 4b in complex with the FLT3-DFG-in homology model over 
110 ps gives only small RMS deviations (0.5 Å to 1.0 Å) compared to the initial complex 
concluding that the protein-ligand complex is highly stable (Figure S31). The vinyl sulfonamide 
substituted sunitinib derivative 4b shows an increase in cytotoxicity towards MV4-11 cells 
compared to the irreversible fragment 2i while the reversible ethyl sulfonamide 4d is ~100-fold 
less cytotoxic. Additionally, inhibition of FLT3(D835Y) is further increased, while inhibition 
Compound 
IC50 / nM Relative Inhibition / % 
t1/2 / mina MV4-11 
(FLT3(ITD)) 
THP1 
(FLT3wt) 
Jurkat 
(FLT3 neg.) 
FLT3(D835Y) FLT3(ITD) 
c = 0.1 µM c = 1 µM c = 0.1 µM 
4a 21 ± 1 > 1 µM > 1 µM 71 90 73 218 
4b 6.0 ± 0.3 > 1 µM > 1 µM 95 100  86 51 
4c > 1 µM n.d. n.d. n.d. n.d. n.d. n.d. 
4d 643 ± 95 n.d. n.d. 32 n.d. n.d. n.d. 
3m 2.3 ± 0.1 172 ±24 44 ± 5 47 90 73 58 
3n 58 ± 16 514 ± 8 298 ± 10 86 95 99 82 
Sunitinib 54 ± 1 > 1 µM > 1 µM 82 96 70 n.d. 
Hypothemycin 15 ± 3  > 1 µM > 1 µM 85 92 91 n.d. 
Crenolanib 12 ± 3 > 1 µM > 1 µM 95 100 97 n.d. 
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decreases by the ethyl sulfonamide compared to sunitinib. Optimization of the irreversible 
fragment 2c to give the sunitinib-derived α-chloro acetamide 4a yields a 2.5-fold increased 
cytotoxicity while the unreactive acetamide derivative 4c is inactive in MV4-11 cells. 4a and 4b 
exhibit both superior cytotoxicity to sunitinib in MV4-11 cells while they retain selectivity 
towards FLT3wt THP1, NOMO1, U937 as well as FLT3-negative Jurkat cells (Figure S32). In 
FLT3(ITD)-positive MOLM-14 cells 4b (IC50 = 7.8 nM) is more cytotoxic than 4a (IC50 = 
26.4 nM) and 3m (IC50 = 11.6 nM). Vinyl sulfonamide 4b shows superior cytotoxicity compared 
to the type I inhibitors midostaurin (~2x), crenolanib (~2x) and hypothemycin (~2.5x) in MV4-
11 cells. While increased cytotoxicity in MV4-11 cells by 4b compared to 4a correlates with 
decreased pFLT3 and pSTAT5 levels, 3m shows higher levels of prosurvival-signaling 
correlating with decreased inhibition in FLT3 kinase assays (Figures 3a, S33). 
 
Reactivity towards Nucleophiles. Half-life of electrophilic compounds was compared in a 
HPLC-based assay using 100-fold excess of nucleophiles to investigate the properties of the 
different CRGs (Figures 3b). While the acrylamide 2f and α-fluoroacetamide 2b are highly stable 
(t1/2 > 24 h), the propargylamide 2g (50 min) as well as the hit-compounds 2c (384 min) and 2i 
(71 min) are less stable. Half-life is decreased by the introduction of the alkaline tertiary amine 
in 4a (218 min) and 4b (52 min). Consequently, pre-incubation of 4b with a 1000x excess of 
glutathione (100 nM inhibitor) for 30 min decreased the inhibition of FLT3(D835Y) kinase 
activity from initial 95% to 68% while incubation for 24h decreases inhibition further (37%). 
Increase of buffer pH leads to a decrease of half-life (28 min, pH 8) while a decrease of pH 
increases half-life (130 min, pH 6.8; Figure S34). The α-N-Cbz-protected lysine, serine and 
threonine amino acids show no conversion with 4b (pH 7.4).  
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Danio Rerio Embryo Toxicity Assay. Biocompatibility and toxicologic effects of irreversible 
FLT3 inhibitors were investigated in Danio rerio embryos, that have been shown to be a 
promising model for drug toxicity screening (Figure 3c).31 Interestingly, in Danio rerio the 
targeted cysteine (DFG-1) is replaced by an alanine residue, suggesting that off-target rather than 
FLT3-dependent toxicity can be observed (Table S6, S7). Comparison of the 2-halo-substituted 
acetamides shows high toxicity  for the bromo- 2d and fluoro- 2b derivative (10 µM inhibitor), 
while the chloro- derivative 2c as well as the reversible acetamide 2a are not lethal up to 96 h 
post incubation (120 hpf). The vinyl sulfonamide 2i as well as hybrid structures 4a and 4b are 
non-toxic at 10 µM comparable to sunitinib, hypothemycin and crenolanib. The bisamino-
pyrimidine 3m shows increased toxicity that is comparable to fragment 1f suggesting a more 
promiscuous mode of action. 
 
Figure 3. (a) Western Blot analysis of FLT3(Y969) phosphorylation and downstream STAT5 
phosphorylation after 1 h incubation with 4b. (b) Half-life of electrophilic inhibitors towards 
reduced glutathione (100x excess, pH 7.4). (c) Toxicity of selected inhibitors on Danio rerio 
embryos (96 hpf, 72 h incubation, 10 µM). (d) Inhibition of FLT3(D835Y) by 4a and 4b is 
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insensitive to high ATP concentrations but is (e) highly dependent on ATP concentration for 
reversible inhibitors. 
 
ATP- and time-dependent inhibition. We further investigated the ATP- and time-
dependency of kinase inhibition by compounds 4a, b and 3m, n in FLT3(D835Y) representing 
the most active compounds from both series. As expected, the reversible binding FLT3 inhibitors 
crenolanib and sunitinib show a strong dependency on ATP concentration, where a 10-fold ATP 
increase (100 µM to 1 mM) leads to an approximately 10-fold decrease of inhibition whereas 
crenolanib (4.2 nM to 42 nM) remains more potent than sunitinib (8.2 nM to 105 nM, Figure 3d, 
e). Since irreversible bond formation leads to non-equilibrium-binding only the initial reversible 
complex, preceding covalent bond formation, is ATP-competitive. Indeed, inhibition of 
FLT3(D835Y) by 4a (67 nM at low ATP, 58 nM at high ATP) as well as 4b (11.6 nM at low 
ATP to 18.6 nM at high ATP) is less vulnerable to increased ATP concentrations. To our 
surprise, 3m and 3n are highly susceptible to high ATP concentrations suggesting low 
inactivation kinetics and thus high competitivity to ATP (Figure S35). Additionally, we 
determined the influence of the pre-incubation time of inhibitor and kinase alone where ATP is 
not competing with inhibitor binding. As expected, the indolinones 4a and 4b as well as the 
bisaminopyrimidines 3m and 3n show increased inhibition of FLT3(D835Y) and FLT3(ITD) 
when pre-incubation time is increased from 5 min to 30 min (Table S8). To determine the Ki and 
kinact values of the most potent covalent FLT3 inhibitors 4a and 4b we evaluated time-dependent 
IC50 values against FLT3(D835Y) (Figure S36). Ki and kinact have been obtained from the plot 
IC50(t) vs t by nonlinear regression (see experimental section). We found that 4a has a lower 
binding affinity (Ki = 10.14 nM) than 4b (Ki = 1.98 nM) but a higher inactivation constant (kinact 
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= 0.0033 / s-1 and 0.0017 / s-1). However, determination of Kinact/Ki shows that 4b is a more 
potent irreversible inhibitor (kinact/Ki  = 0.84 µM
-1 s-1) than 4a (kinact/Ki  = 0.33 µM
-1 s-1).” 
 
Trypsin-digest and MALDI-MS of covalently modified FLT3. Since compounds 4a and 4b 
represent the most active compounds in this study covalent modification of Cys828 was 
confirmed by tryptic in-gel digest of FLT3wt, that was considered to yield the modified 
octapeptide IC828DFGLAR that could be detected by MALDI mass spectrometry. Standard 
denaturation and alkylation protocol using dithiothreitol and 2-iodo acetamide allowed detection 
of the single acetamide-substituted peptide with good agreement of the calculated and found 
masses and the modeled and measured isotopic pattern (Figure S37 – S41). Subsequent MS/MS 
allowed detection of numerous fragments of this sequence. Pre-incubation of FLT3wt with 2i, 
hypothemycin, 4a and 4b allowed detection of calculated masses with small errors confirming 
covalent modification of Cys828 by the key compounds in this study.  
 
Kinase selectivity of 4b and activity towards resistance-conferring mutations. We chose 
compound 4b as lead structure in this project as it shows the strongest inhibition of the isolated 
kinase and strongest cytotoxicity and further investigated kinase selectivity as well as activity in 
drug-resistant mutations. Selectivity of the most potent inhibitor 4b was determined in a panel of 
34 kinases at 100 nM inhibitor (Figure 4a). Kinases, that are inhibited by sunitinib, were selected 
for testing based on available Kd values for sunitinib and for containing the homologous CDFG 
motif (Table S9, Figure S42). As expected, FLT3 (95%) and FLT3(D835Y) (99%) are potently 
inhibited. Surprisingly, other kinases of the PDGF receptor family containing the conserved 
DFG-1 cysteine are significantly less inhibited, including c-KIT (34%), PDGFRα (24%) and 
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PDGFRβ (14%). This is remarkable as they all share high sequence similarities (>70%) to FLT3 
and exhibit single-digit to sub-nanomolar Kd values for sunitinib.
32 Interestingly, less related 
kinases (30 to 40% sequence similarity) containing the CDFG motif (ERK1, ERK2, GSK3α, 
GSK3β) are not inhibited at 100 nM 4b while being reported targets of hypothemycin.10 4b may 
also covalently modify the homologous serine residue (DFG-1) as the Ret kinase (96%) is 
strongly inhibited. Interestingly, 5-amino indolinones have been reported to be potent Ret and 
FLT3 inhibitors while superposition of the FLT3 model and Ret cocrystal structure is in good 
accordance  (RMSD = 0.7 Å, Figure S43).33 The homolog alanine  and glycine residues are 
tolerated by 4b (Lyn, Lck, Axl, IRAK1; 93% to 81% inhibition) suggesting that hydrogen bond 
interactions to the conserved lysine may account for increased affinity compared to sunitinib 
while a steric clash with CysSγ or SerOγ is prevented. We further assessed our lead compound 4b 
using the KinomeScan screening platform, where numerous FLT3 inhibitors have been assessed 
before (Figure 4b).34-35 
 
Figure 4. (a) Selectivity of 4b in a panel of 34 kinases.36 (b) Kd values of 4b and inhibitors in 
clinical trials in a panel of FLT3-mutants. (c) Relative inhibition by time (IC50(crenolanib)/ 
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IC50(4b)). (d) Effect of inhibitor wash-out after 2 h, 8 h, 24 h incubation and read-out at 72 h in 
MV4-11 cells.  
 
Sunitinib and crenolanib show higher affinity towards FLT3wt and FLT3(ITD) than 4b, while 
midostaurin is less efficient. Interestingly, sunitinib showed a ~6-fold increased Kd in 
FLT3(ITD) but inhibition despite cell viability in FLT3-ITD was ~10-fold increased for 4b. 
Crenolanib and quizartinib lose affinity towards dual ITD and point-mutated FLT3, while 
affinity is increased for 4b. Especially towards the drug-resistant FLT3(ITD, F691L) mutation, 
4b shows a ~15-fold increased affinity compared to crenolanib. Comparison of the affinity of 4b 
for the non-autoinhibited (Kd = 2.3 nM) and the autoinhibited state (Kd = 65 nM) of FLT3 shows 
a 28-fold decrease that is similar to type I inhibitors as sunitinib and midostaurin while type II 
inhibitors like sorafenib and quizartinib typically give a 100- to 1000-fold shift in affinity.37 
 
Time-dependent inhibition of cell viability. To monitor the onset of cytotoxicity we 
compared crenolanib and 4b in a real-time cell viability assay with MV4-11 cells (Figure 4c, 
Figure S44). While cytotoxicity became detectable already after 2 h, robust fitting of cell 
viability IC50 was possible after 8 h for both compounds. Cytotoxicity by 4b relative to 
crenolanib was maximal at 18 h (4.4-fold) and plateaus to ~1.5x stronger inhibition for 4b after 
24 h until the end of the assay (77 h). Interestingly, short incubation times (2 h, 8 h) followed by 
wash-out of the inhibitor and incubation in inhibitor-free medium negatively affects the 
performance of 4b compared to crenolanib (Figure 4d). However, potency of 4b is increased by 
incubation times longer than 24 h suggesting that rapid de novo synthesis of FLT3-ITD may lead 
to resistance to short incubation times of irreversible inhibitors. However, onset of inhibition by 
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4b demonstrated by decreased pFLT3 and downstream pSTAT5 levels is in the single-digit 
nanomolar range after 1 h (Figure 3a). 
 
Evaluation of BODIPY-labeled Activity-based Probes. We further aimed to modify the hit 
compounds 2c and 2i with a boron-dipyrromethene (BODIPY) label attached to the solvent-
exposed site of the fragment to image irreversible protein binding similar to a recently reported 
Ibrutinib-based probe38 (Figure 5a, b). Synthesis was performed similar to reported work. 
 
 
 
Figure 5. (a) Structure of fluorescent probes 5a and 5b and the reversible inhibitors 5c and 5d. 
(b) Binding model of 5a in FLT3. (c) Western blot of FLT3(D835Y) incubated with 5a or 5c 
(100 µM) and pre-treatment with IAA (10 mM) or 4b (100 µM) followed by incubation with 5a. 
(d) Binding of 5a – d (50 µM) to FLT3(D835Y) and pre-treatment with 4b and hypothemycin 
(HY) followed by incubation with 5a. (e) Binding of 5a (10 µM) to FLT3(D835Y) and pre-
treatment with 3m, 3n, 4a and sunitinib (SU, each 100 µM) followed by incubation with 5a (10 
µM). 
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Inhibition of FLT3(D835Y)  by 5a (89%) and 5b (55%) was decreased compared to 4a and 4b 
(1 µM inhibitor) but still superior to the corresponding reversible inhibitors 5c (34%) and 5d 
(23%) (Figure S45). Incubation of FLT3(D835Y) with probes 5a - d and subsequent standard gel 
electrophoresis and Western blot allows fluorescent detection of covalent binding for 5a and 5b 
(50 µM, Figure 5c, d, Figure S46) while acetamide 5d shows no fluorescence. Interestingly, 
trifluoroacetamide 5c shows similar binding compared to 5b (18% at 100 µM and 7% at 50 µM; 
relative integrated density compared to 5a). We thus pre-treated FLT3(D835Y) with reversibly 
and irreversibly acting inhibitors following incubation with fluorescent probe 5a that gave the 
highest fluorescence signal and signal to background ratio. Treatment of FLT3(D835Y) with 
10 mM IAA almost completely abrogated fluorescence after treatment with 5a (100 µM). 
Incubation with 4b (100 µM) gave a small decrease of fluorescence with 100 µM of probe 5a 
(-28%) while incubation with 50 µM probe decreased fluorescence signal further (-41%) and 
comparable to treatment with hypothemycin (-52%). A similarly decreased fluorescence was 
observed after pre-incubation with bisaminopyrimidines 3m (-55%), 3n (-90%) and indolinone 
4a (-68%). Incubation with the reversible inhibitor sunitinib (-29%) slightly decreases 
fluorescence suggesting covalent binding of the probe in the ATP site where the 10x excess of 
pre-treated inhibitor strongly competes with the reversible complex preceding covalent binding 
of the irreversible probe (Figure 5e). Additionally, gastrointestinal uptake of probes 5a and 5b 
could be detected in Danio rerio embryos (Figure S47). 
Conclusions and Perspective 
In summary, we have discovered irreversible binding FLT3 inhibitors that overcome drug-
resistant mutations of FLT3. A focused screening library was designed by attachment of 
chemically reactive groups to potent reversible binding fragments. Subsequent covalent docking 
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identified two privileged scaffolds that gave numerous FLT3 inhibitors with improved 
cytotoxicity in FLT3-driven cell lines. Hybridization with the parental sunitinib scaffold gave the 
most potent compound 4b (BSc5371) that shows increased cytotoxicity in comparison to drugs 
in current clinical trials and is selective over closely related kinases. Subsequent development of 
an activity-based probe enabled imaging of covalent binding and competition with non-
fluorescent inhibitors. The screening strategy presented here is adaptable to many drug targets 
and may serve as a blueprint for the rational in silico design of covalent drugs enabling more 
time- and cost-efficient drug discovery. 
 
Experimental Section 
Covalent Virtual Screening and Filter Strategy 
Homology Model  
The protein sequence of FLT3 (PDB: 1RJB) and the structure of cKIT in complex with ADP 
(PDB: 1PKG) was obtained from the protein databank. Amino acid residues that are only 
described in one of the models and are distant from the ATP-binding pocket were discarded (see 
Table S1 and Figure S1). The homology model was built using Molecular Operating 
Environment 2014.09 (MOE, Chemical Computing Group). Protein sequences were aligned and 
the sequence of 1RJB was modeled on the template 1PKG using 25 mainchain models and the 
Amber12:EHT forcefield. RMSD between the template and the final model is 0.01 Å. The 
Ramachandran Plot of the final model displays four geometric outliers that are all distant from 
the ATP-binding pocket and were not further optimized. 
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Reversible Docking 
Initial pharmacophores for the 13 selected reversible inhibitor scaffolds were built using a 
superposition of reported crystal structures and the FLT3 DFG-in homology model to enable 
robust evaluation of the most likely reversible binding pose (Figures S6 to S18). Input structures 
were drawn using ChemBioDraw Ultra 14.0 and energy minimized using MOE and the 
MMFF94x forcefield. The final selected docking pose that serves as a template was used to 
define the pharmacophore for the covalent virtual screening. 
Covalent Docking using Docktite 
All compounds studied were docked in the ATP-binding site where the reversible inhibitor 
serves as a site indicator and defines the pharmacophore. Covalent docking was performed using 
the Docktite SVL script set for MOE. Input structures were generated by modification of the 
reversible docked inhibitor scaffold with a chemical reactive group at an appropriate site to give 
128 inhibitors (see figure S5). The chemical reactive groups are tagged and attached to the 
covalent attachment point to give 160 sidechain-attached ligands that served as ligands for 
covalent docking. Pharmacophores were generated automatically regarding the features of the 
covalent attachment point (R = 0.4 Å) and have been enhanced using aryl and hydrogen-bond 
donor and acceptor features (R = 1.5 Å, see figure S6B to S18B). The pharmacophore feature of 
the nucleophilic sulfur atom is increased to 3.0 Å to allow conformational flexibility of the 
attachment point, while the other heavy atoms of Cys828 are unchanged to resemble the initial 
input conformation of the homology model. The Cys828 residue and the N- and C-terminal 
amide group were removed from the receptor for covalent docking. Docking was performed 
using MOE´s rigid receptor docking function and the Amber12:EHT forcefield. 5000 
conformations of the attached ligands are sampled and filtered by the pharmacophore model. 
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Rescoring of the placements was performed using the London dG scoring function and 100 poses 
are subjected to grid-based minimization and rescored using London dG. The force constant of 
the pharmacophore restraint was set to 1e+9. The docking was performed in batch jobs and was 
finished after approximately 48 h using a custom-built 64-bit computer system (Intel i7-4790K 
CPU 4*4GHz, 8 GB Ram 2800 MHz). The attached sidechain was then cleaved from the 
inhibitor using Docktite to allow more robust rescoring of the ligand. 831 poses have been 
retained and are subjected to the filter strategy. 
Filter strategy 
In the first step for scaffold selection, DSX rescoring was performed using the linux-based 
standalone version. Ligands that contain any of the three characteristic backbone interactions 
with the hinge region (gatekeeper +1 residue Glu692 backbone donor interaction; and/or 
gatekeeper +3 residue Cys694 backbone donor/acceptor interaction) are selected using the 
Protein-Ligand Interaction Fingerprints (PLIFs) function of MOE (404 poses remaining). From 
these poses only the top 5 poses of each ligand are retained (319 poses remaining). In the last 
filter step, ligands with a ligand efficiency of more than -0.5 HA/kcal are discarded (LEV = 
(London dG Score) / (number of heavy atoms). Redocking of the experimental validated hits was 
done like the screening method using forcefield minimization and an enhanced pharmacophore 
radius of the scaffold pharmacophore (R = 2Å).  
Molecular Dynamics 
The molecular dynamics simulations of 4b were performed using MOE2016.09 and the NPA 
algorithm39 starting from the top-scored docking pose of 4b in the FLT3 DFG-in homology 
model. 10 picoseconds of equilibration are followed by a 100 ps production step using a time 
step of 0.1 ps. All bond lengths have been constrained. Time step for the equation of motions 
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was set to 0.001. Temperature was set to 300K. The time-dependent RMSD values are given in 
the SI (Figure S31). 
Chemistry 
General remarks 
Solvents and chemicals were purchased from ABCR, Acros Organics, Alfa Aesar, Deutero 
Gmbh, Fluka, Grüssing Gmbh, Merck, Carl Roth, Sigma-Aldrich and VWR and were used 
without further purification unless stated otherwise. Qualitative analytical thin layer 
chromatography was performed using silica gel 60 plates with fluorescent indicator F254 from 
Merck. Developed plates were dried and observed under UV light (254 or 365 nm). Silica 
chromatography was performed using silica gel 60 (0.015 – 0.04 mm particle size) from Merck 
and an isocratic solvent mixture. Flash chromatography was performed using a Teledyne ISCO 
Combiflash Rf 4x system with pre-packed silica columns obtained from Telos. The column was 
conditioned with solvent to the starting concentration of the gradient. Peaks were detected at 
214/254 nm (reversed-phase chromatography) or 254/280 nm (normal phase chromatography). 
1H and 13C-NMR spectra were recorded on a Bruker AR 300 (1H at 300 MHz, 13C at 75 MHz) or 
a Bruker DRX 500 spectrometer (1H at 500 MHz, 13C at 126 MHz). The specific frequency and 
solvents are stated for each experiment. Chemical shifts δ are expressed in ppm using the solvent 
residual proton signal as reference. Signal splitting patterns are described as singlet (s), doublet 
(d), triplet (t), quartet (q), multiplet (m) or a combination thereof. Coupling constants J are 
rounded to one decimal place and given in Hz. The spectra were evaluated using MestReNova 11 
by Mestrelab Research. High Performance Liquid Chromatography was performed with an 
Agilent 1100 system using a phenomenex synergi polar reversed phase column (4 µm particle 
size, 150 x 3.0 mm, pore size 80 Å) connected to a variable wavelength detector. Mobile phase 
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consists of water/acetonitrile + 0.1% trifluoro acetic acid forming a linear gradient starting with 
30% water (held for 1 minute) increased to 90% acetonitrile over 10 min and held for one min 
with a constant flow of 1 ml/min. Microwave assisted synthesis were performed in a Biotage 
Initiator plus microwave reactor using the conditions stated in the corresponding experiments. 
EI-MS spectra were recorded on a double focused mass spectrometer MAT95. ESI-MS was 
obtained using a Bruker Daltonics qTOF spectrometer. All compounds used in biochemical 
assays have a purity of more than 95% as determined by HPLC and are reported at the 
corresponding experiments. 
N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenylpyrimidine-2,4-diamine (1a). To a solution 
of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (150 mg, 0.72 mmol, 1.0 equiv) in 
n-butanol (4 ml) was added aniline (67 mg, 0.72 mmol, 1.0 equiv) and 37% hydrochloric acid 
(20 µl). The mixture was stirred for 24 h at 100°C, cooled to room temperature and kept at 4°C 
overnight. The precipitate was isolated by filtration, washed with cyclohexane and 
dichloromethane and purified by reversed-phase flash chromatography (acetonitrile/H2O = 
10 to 100%) to give 1a as a colorless amorphous solid. Yield: 115 mg, 0.432 mmol, 60%. 1H 
NMR (500 MHz, DMSO-d6) δH (ppm) = 12.40 (s, 1H), 11.03 (s, 1H), 10.65 (s, 1H), 8.00 (d, J = 
7.1 Hz, 1H), 7.59 (d, J = 7.7 Hz, 2H), 7.44 (t, J = 7.9 Hz, 2H), 7.24 (t, J = 7.4 Hz, 1H), 6.54 (s, 
1H), 6.22 (s, 1H), 2.20 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 159.9, 159.4, 159.1, 
153.1, 146.0, 139.1, 137.0, 128.9, 124.8, 117.9, 96.8, 10.6. MS (EI): m/z = 266 [M] +. HPLC 
(254 nm): tR = 1.827 min (99.4713%).  
(Z)-3-Benzylideneindolin-2-one (1b).40 To a solution of indolin-2-one (200 mg, 
1.5 mmol, 1.0 equiv) and benzaldehyde (159 mg, 1.502 mmol, 1.0 equiv) in tetrahydrofuran 
(4 ml), piperidine (25 µl) was added and the mixture was heated in a microwave reactor at 120°C 
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for 90 min. The solvent was evaporated, and the crude product purified by flash chromatography 
(dichloromethane/MeOH = 0 to 10%) to yield the product as a yellow amorphous solid. Yield: 
122 mg, 0.55 mmol, 37%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 10.61 (s, 1H), 7.75 – 7.70 
(m, 2H), 7.66 (s, 1H), 7.60 – 7.45 (m, 4H), 7.25 (td, J = 7.7, 1.2 Hz, 1H), 6.95 – 6.78 (m, 2H). 
13C NMR (126 MHz, DMSO-d6) δC (ppm) = 168.6, 143.0, 135.7, 134.5, 130.2, 129.6, 129.2, 
128.7, 127.7, 122.3, 121.1, 120.9, 110.1. MS (ESI): m/z = 244.08 [M+Na] +. HPLC (254 nm): tR 
= 6.412 min (96.7002%).  
 3-Phenylimidazo[1,2-a]pyridine (1c).41 To a solution of imidazo[1,2-a]pyridine 
(100 mg, 0.846 mmol, 1.0 equiv) and bromobenzene (251 mg, 1.69 mmol, 2.0 equiv) in dry 
DMF (4 ml) was added Pd(OAc)2 (19 mg, 0.085 mmol, 0.1 equiv) and KOAc (166 mg, 
1.69 mmol, 2.0 equiv) and the mixture was degassed under argon for 30 min. The reaction 
mixture was stirred in a microwave reactor at 160°C for 1 h. Then it was cooled to room 
temperature poured, in a mixture of saturated aqueous NaHCO3 solution (10 mL) and ethyl 
acetate (20 ml). The organic layer was washed with saturated aqueous sodium bicarbonate 
solution (2 x 10 ml) and water (3 x 10 ml), dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by reversed-phase flash chromatography 
(acetonitrile/H2O = 10 to 100%) to give 1c as a colorless amorphous solid. Yield: 95 mg, 0.49 
mmol, 58%. 1H NMR (500 MHz, CDCl3
 + 10% DMSO-d6)  δH (ppm) = 8.41 (d, J = 6.8 Hz, 1H), 
8.15 (d, J = 9.0 Hz, 1H), 7.84 (s, 1H), 7.77 (t, J = 7.9 Hz, 1H), 7.59 – 7.46 (m, 5H), 7.29 (t, J = 
6.9 Hz, 1H). 13C NMR (126 MHz, CDCl3 + 10% DMSO-d6)  δC (ppm) = 140.3, 132.5, 130.8, 
129.9, 129.1, 127.3, 124.9, 124.6, 121.0, 117.3, 114.2. MS (EI): m/z = 194 [M] +. HPLC (254 
nm): tR = 5.602 min (95.8210%).  
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6,7-Dimethoxy-N-phenylquinazolin-4-amine (1d). To a solution of 4-chloro-6,7-
dimethoxyquinazoline (50 mg, 0.22 mmol, 1.0 equiv) in isopropyl alcohol (2 ml) was added 
aniline (32 mg, 0.34 mmol, 1.55 equiv). The mixture was refluxed for 16 h and cooled to room 
temperature. The precipitate formed was isolated by filtration and washed with ethyl acetate 
(1 ml) twice to give the product as a colorless amorphous solid. Yield: 62 mg, 0.216 mmol, 98%. 
1H NMR (500 MHz, DMSO-d6) δH (ppm) = 11.51 (s, 1H), 8.81 (s, 1H), 8.40 (s, 1H), 7.79 – 7.66 
(m, 2H), 7.50 (t, J = 7.9 Hz, 2H), 7.41 (s, 1H), 7.38 – 7.29 (m, 1H), 4.04 (s, 3H), 4.00 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δC (ppm) = 158.2, 156.2, 150.2, 148.6, 136.86, 135.4, 129.5, 
128.7, 126.3, 124.9, 107.2, 104.1, 99.7, 57.0, 56.4. MS (EI): m/z = 281 [M] +. HPLC (254 nm): tR 
= 5.997 min (97.2261%).  
3,5-Diphenyl-1H-pyrrolo[2,3-b]pyridine (1e). 3,5-Diphenyl-1-tosyl-1H-pyrrolo[2,3-b]-
pyridine (56 mg, 0.13 mmol, 1.0 equiv) was dissolved in a mixture of MeOH (15 ml) and 
aqueous 4 N sodium hydroxide (0.2 ml) and stirred at 50°C for 24 h. The reaction mixture was 
cooled to room temperature and adjusted to pH 5-6 by addition of aqueous 2 N hydrochloric 
acid. The mixture was concentrated and treated with water (10 ml) and ethyl acetate (10 ml). The 
aqueous layer was extracted with ethyl acetate (10 ml) three times and the combined organic 
layers were washed with brine, dried over MgSO4 and the solvent was evaporated. The crude 
product was purified by silica chromatography (cyclohexane/ethyl acetate = 1/1) to give the title 
compound as a colorless amorphous solid. Yield: 26 mg, 0.095 mmol, 73%. 1H NMR (500 MHz, 
DMSO-d6) δH (ppm) = 11.99 (s, 1H), 8.57 (d, J = 2.1 Hz, 1H), 8.43 (d, J = 2.0 Hz, 1H), 7.91 (d, J 
= 2.6 Hz, 1H), 7.78 (ddd, J = 12.7, 8.2, 1.1 Hz, 4H), 7.47 (ddd, J = 19.7, 10.9, 4.6 Hz, 4H), 7.41 
– 7.35 (m, 1H), 7.30 – 7.23 (m, 1H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 148.6, 141.9, 
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139.0, 134.9, 128.9, 128.9, 128.8, 127.1, 126.9, 126.39, 125.7, 125.4, 124.6, 117.3, 114.7. MS 
(EI): m/z = 270 [M] +. HPLC (254 nm): tR = 2,653 min (97,4023%).  
N4-(5-Cyclopropyl-1H-pyrazol-3-yl)-N2-phenylpyrimidine-2,4-diamine (1f). To a 
solution of 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidin-4-amine (200 mg, 
0.849 mmol, 1.0 equiv) in n-butanol (3.2 ml) was added aniline (79 mg, 0.849 mmol, 1.0 equiv) 
and 37 % hydrochloric acid (40 µl). The mixture was stirred for 24 h at 100°C and subsequently 
cooled to room temperature and kept at 4°C overnight. The precipitate was isolated by filtration, 
washed with cyclohexane and dichloromethane and purified by reversed-phase flash 
chromatography (acetonitrile/H2O =  10 to 100%) to give 1f as a colorless amorphous solid. 
Yield: 159 mg, 0.54 mmol, 64%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 12.48 (s, 1H), 
11.20 (s, 1H), 10.68 (s, 1H), 8.21 – 7.81 (m, 1H), 7.56 – 7.47 (m, 2H), 7.44 (t, J = 7.7 Hz, 2H), 
7.27 (d, J = 7.4 Hz, 1H), 6.46 (s, 1H), 6.04 (s, 1H), 1.83 (dt, J = 8.8, 3.8 Hz, 1H), 1.11 – 0.89 (m, 
2H), 0.55 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 176.6, 159.7, 157.4, 152.7, 146.5, 
145.7, 142.2, 136.5, 129.0, 125.4, 123.4, 99.2, 93.3, 7.9, 6.7. MS (ESI): m/z = 293.1 [M+H] +. 
HPLC (254 nm): tR = 1.778 min (98.6020%).  
(Z)-3-((1H-Pyrrol-2-yl)methylene)indolin-2-one (1g).40 To a solution of indolin-2-one 
(200 mg, 1.5 mmol, 1.0 equiv) and 1H-pyrrole-2-carbaldehyde (142 mg, 1.502 mmol, 1.0 equiv) 
in tetrahydrofuran (4 ml), piperidine (25 µl) was added and the mixture was heated in a 
microwave reactor at 120°C for 90 min. The solvent was evaporated, and the crude product 
purified by flash chromatography (dichloromethane/MeOH = 0 to 10%) to yield the product as a 
yellow amorphous solid. Yield: 131 mg, 0.62 mmol, 42%. 1H NMR (300 MHz, DMSO-d6) δH 
(ppm) =  13.34 (s, 1H), 10.88 (s, 1H), 7.74 (s, 1H), 7.66 – 7.60 (m, 1H), 7.35 (td, J = 2.7, 1.4 Hz, 
1H), 7.15 (td, J = 7.6, 1.2 Hz, 1H), 7.00 (td, J = 7.6, 1.1 Hz, 1H), 6.89 (dt, J = 7.6, 0.9 Hz, 1H), 
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6.84 (dt, J = 3.6, 1.7 Hz, 1H), 6.36 (dt, J = 3.7, 2.3 Hz, 1H). 13C NMR (75 MHz, DMSO-d6) 
δC (ppm) = 169.2, 138.9, 129.5, 126.8, 126.3, 125.6, 125.1, 121.2, 120.2, 118.5, 116.8, 111.4, 
109.5. MS (EI): m/z = 210.0 [M] +. HPLC (254 nm): tR = 2.967 min (98.4849%).  
 (Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)acetamide (2a). To a solution 
of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (100 mg, 0.444 mmol, 1.0 equiv) in 
THF (20 ml) at 0°C was added triethylamine (123 µl, 0.888 mmol, 2.0 equiv) and acetyl chloride 
(35 µl, 0.488 mmol, 1.1 equiv). The solution was warmed to room temperature and stirred for 
2 h. The reaction was quenched by the addition of brine (20 ml) and ethyl acetate (20 ml) and the 
organic layer was washed with 0.1 N aqueous HCl (2 x 10 ml) and 0.1 N aqueous NaOH solution 
(2 x 10 ml). The organic layer was dried over Na2SO4, the solvent was removed, and the crude 
product was purified by flash chromatography (dichloromethane/MeOH = 1 to 10%) to give the 
product as a yellow amorphous solid. Yield: 69 mg, 0.257 mmol, 58%. 1H NMR (500 MHz, 
DMSO-d6) δH (ppm) = 13.36 (s, 1H), 10.80 (s, 1H), 9.80 (s, 1H), 7.92 (d, J = 2.0 Hz, 1H), 7.60 
(s, 1H), 7.37 (dt, J = 4.1, 2.0 Hz, 1H), 7.20 (d, J = 8.3, 2.0 Hz, 1H), 6.93 (dt, J = 3.5, 1.7 Hz, 
1H), 6.83 (d, J = 8.3 Hz, 1H), 6.37 (dt, J = 3.6, 2.4 Hz, 1H), 2.05 (s, 3H). 13C NMR (126 MHz, 
DMSO-d6) δC (ppm) = 169.3, 167.8, 134.9, 133.5, 129.5, 126.1, 125.7, 125.1, 120.6, 118.8, 
117.0, 111.4, 110.5, 109.4, 40.1, 39.9, 39.7, 39.5, 39.4, 39.2, 39.1, 23.8. MS (ESI) m/z = 268.1 
[M+H] +. HPLC (254 nm): tR = 3.843 min (100.0000%).  
 (Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-2-fluoroacetamide (2b). 2d 
(124 mg, 0.355 mmol, 1.0 equiv) and potassium fluoride (206 mg, 3.55 mmol, 10.0 equiv) were 
suspended in diethylene glycol (5 ml) and stirred at 130°C for 5 h. The reaction mixture was 
cooled to room temperature and diluted with water (100 ml), extracted with dichloromethane 
(2 x 50 ml), dried over Na2SO4 and the solvent was evaporated. The residue was purified by 
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silica chromatography (dichloromethane/MeOH=20/1) to give the title compound as a yellow 
amorphous solid. Yield: 35 mg, 0.123 mmol, 35%. 1H NMR (300 MHz, DMSO-d6) δH (ppm) = 
13.34 (s, 1H), 10.86 (s, 1H), 9.97 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.62 (s, 1H), 7.49 – 7.24 (m, 
2H), 7.01 – 6.78 (m, 2H), 6.36 (dt, J = 3.8, 2.3 Hz, 1H), 5.06 (s, 1H), 4.90 (s, 1H). 13C NMR (75 
MHz, DMSO-d6) δC (ppm) = 169.3, 165.6, 165.4, 135.5, 131.9, 129.4, 126.3, 125.8, 125.1, 120.8, 
119.7, 116.7, 111.4, 109.4, 81.2, 78.8. MS (ESI) m/z = 286.1 [M+H] +. HPLC (254 nm): tR = 
4.282 min (95.1175%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-2-chloroacetamide (2c). To 
a solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (106 mg, 0.47 mmol, 
1.0 equiv) in THF (15 ml) at 0°C was added pyridine (57 µl, 0.71 mmol, 1.5 equiv) and chloro 
acetyl chloride (49 µl, 0.611 mmol, 1.3 equiv). The solution was warmed to room temperature 
and stirred for 1 h. The reaction was quenched by the addition of brine (20 ml) and ethyl acetate 
(20 ml) and the organic layer was washed with saturated aqueous sodium bicarbonate solution 
(20 ml) and brine (20 ml), dried with Na2SO4 and the solvent was evaporated. The residue was 
purified by silica chromatography (dichloromethane/MeOH=20/1) to give the title compound as 
a yellow amorphous solid. Yield: 53 mg, 0.18 mmol, 37%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) = 13.42 (s, 1H), 10.66 (s, 1H), 10.07 (s, 1H), 7.89 (d, J = 1.9 Hz, 1H), 7.47 (s, 1H), 7.23 – 
7.17 (m, 2H), 6.83 – 6.76 (m, 2H), 6.31 (dt, J = 3.6, 2.3 Hz, 1H), 4.17 (s, 2H). 13C NMR (126 
MHz, DMSO-d6) δC (ppm) = 169.3, 164.2, 135.5, 132.3, 129.5, 125.9, 125.2, 124.9, 120.1, 118.8, 
117.0, 111.2, 110.5, 109.3, 43.3. MS (ESI) m/z = 302.1 [M+H] +. HPLC (254 nm): tR = 
4.985 min (96.1842%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-2-bromoacetamide (2d). To 
a solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (247 mg, 1.1 mmol, 1.0 equiv) 
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in dry THF (20 ml) at 0°C was added diisopropylethylamine (382 µl, 2.2 mmol, 2.0 equiv) and 
bromo acetyl bromide (242 mg, 1.2 mmol, 1.1 equiv). The solution was warmed to room 
temperature and stirred for 1 h. The reaction was quenched by the addition of brine (20 ml) and 
ethyl acetate (40 ml), the organic layer was washed with saturated aqueous sodium bicarbonate 
solution (20 ml) and brine (20 ml), dried with Na2SO4 and the solvent was evaporated. The 
residue was purified by silica chromatography (dichloromethane/MeOH=20/1) to give the title 
compound as a yellow amorphous solid. Yield: 163 mg, 0.472 mmol, 47%. 1H NMR (300 MHz, 
DMSO-d6) δH (ppm) = 13.34 (s, 1H), 10.86 (s, 1H), 10.27 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.65 
(s, 1H), 7.36 (q, J = 2.1 Hz, 1H), 7.20 (dd, J = 8.4, 2.0 Hz, 1H), 7.00 – 6.77 (m, 2H), 6.36 (dt, J = 
4.1, 2.3 Hz, 1H), 4.04 (s, 2H). 13C NMR (75 MHz, DMSO-d6) δC (ppm) = 169.2, 164.4, 135.4, 
132.6, 129.5, 126.4, 125.9, 125.2, 120.8, 118.9, 116.7, 111.5, 110.5, 109.6, 30.4. MS (ESI) m/z = 
346.03 [M+H] +. HPLC (254 nm): tR = 5.145 min (95.9804%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)propionamide (2e). To a 
solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (57 mg, 0.253 mmol, 1.0 equiv) 
in acetonitrile (4 ml) was added triethylamine (35 µl, 0.235 mmol, 1.0 equiv), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (97 mg, 0.51 mmol, 2.0 equiv) and 
propanoic acid (23 µl, 0.304 mmol, 1.2 eq). The reaction was stirred at room temperature 
overnight and water (20 ml) and ethyl acetate (20 ml) were added. The organic layer was washed 
with saturated aqueous sodium bicarbonate solution (20 ml) and brine (20 ml), dried over sodium 
sulfate and the solvent was evaporated. The residue was purified by silica chromatography 
(dichloromethane/MeOH=20/1) to give the title compound as a yellow amorphous solid. Yield: 
21 mg, 0.075 mmol, 30%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 13.55 – 13.29 (m, 1H), 
10.52 (s, 1H), 9.50 (s, 1H), 7.96 – 7.91 (m, 1H), 7.39 (s, 1H), 7.18 – 7.13 (m, 2H), 6.76 (d, J = 
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8.3 Hz, 1H), 6.72 (dt, J = 3.6, 1.7 Hz, 1H), 6.30 (dt, J = 3.7, 2.3 Hz, 1H), 2.33 (q, J = 7.6 Hz, 
2H), 1.15 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 171.8, 169.4, 134.9, 
133.2, 129.5, 125.5, 125.0, 124.6, 119.7, 118.6, 117.3, 111.1, 110.4, 109.2, 29.5, 9.6. MS (EI) 
m/z = 281 [M] +. HPLC (254 nm): tR = 4.881 min (95.0225%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)acrylamide (2f). To a 
solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (153 mg, 0.679 mmol, 
1.0 equiv) in dichloromethane (25 ml) at 0°C was added triethylamine (188 µl, 1.358 mmol, 
2.0 equiv) and acryloyl chloride (60 µl, 0.75 mmol, 1.1 equiv). The solution was warmed to 
room temperature and stirred overnight. The reaction was quenched by the addition of water 
(20 ml) and ethyl acetate (20 ml) and the organic layer was washed with saturated aqueous 
sodium bicarbonate solution (2 x 20 ml) and brine (20 ml) and dried over Na2SO4. The solvent 
was evaporated, and the crude product was purified by silica chromatography 
(dichloromethane/MeOH = 20/1) to give the title compound as a yellow amorphous solid. Yield: 
65 mg, 0.232 mmol, 34%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 13.33 (s, 1H), 10.83 (s, 
1H), 10.10 (s, 1H), 8.00 (d, J = 1.9 Hz, 1H), 7.63 (s, 1H), 7.45 – 7.24 (m, 2H), 7.02 – 6.80 (m, 
2H), 6.45 (dd, J = 16.9, 10.1 Hz, 1H), 6.37 – 6.15 (m, 1H), 5.75 (dd, J = 10.1, 2.0 Hz, 1H). 13C 
NMR (126 MHz, DMSO-d6) δC (ppm) = 169.3, 163.0, 135.2, 133.0, 131.9, 129.4, 126.4, 126.3, 
125.9, 125.2, 120.8, 119.0, 116.7, 111.5, 110.6, 109.6. MS (ESI) m/z = 280.5 [M+H] +. HPLC 
(254 nm): tR = 4.752 min (95.2080%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)propionamide (2g). To a 
solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (115 mg, 0.51 mmol, 1.0 equiv) 
in acetonitrile (4 ml) at 0°C was added triethylamine (71 µl, 0.51 mmol, 1.0 equiv), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (195 mg, 1.02 mmol, 2.0 equiv) and 
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propargylic acid (38 µl, 0.612 mmol, 1.2 equiv) and stirred overnight at room temperature.  The 
reaction was quenched by the addition of brine (20 ml) and ethyl acetate (20 ml) and the organic 
phase was washed with 0.1 N aqueous HCl (2 x 10 ml) and 0.1 N aqueous NaOH (2 x 10 ml). 
The organic phase was dried over Na2SO4, the solvent was removed, and the crude product was 
purified by flash chromatography (dichloromethane/MeOH = 1 to 10%) to give the product as a 
yellow amorphous solid. Yield: 61 mg, 0.22 mmol, 43%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) = 13.42 (s, 1H), 10.72 (s, 1H), 10.54 (s, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.49 (s, 1H), 7.33 – 
7.19 (m, 2H), 6.86 – 6.75 (m, 2H), 6.32 (dt, J = 3.7, 2.3 Hz, 1H), 4.02 (s, 1H). 13C NMR (126 
MHz, DMSO-d6) δC (ppm) = 169.3, 149.4, 135.6, 132.2, 129.4, 126.0, 125.1, 125.1, 120.3, 119.0, 
111.3, 110.7, 109.3, 75.9. MS (EI) m/z = 277 [M] +. HPLC (254 nm): tR = 4.639 min 
(95.7320%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)ethanesulfonamide (2h). To 
a solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (57 mg, 0.25 mmol, 1.0 equiv) 
in THF (5 ml) at 0°C was added diisopropyl ethyl amine (44 µl, 0.25 mmol, 1.0 equiv) and 
ethane sulfonyl chloride (24 µl, 0.25 mmol, 1.0 equiv). The solution was warmed to room 
temperature and stirred overnight. The reaction was quenched by the addition of brine (20 ml) 
and ethyl acetate (20 ml) and the organic layer was washed with saturated aqueous sodium 
bicarbonate solution (20 ml) and brine (20 ml) and dried with Na2SO4. The solvent was 
evaporated, and the crude product was purified by flash chromatography 
(dichloromethane/MeOH = 1 to 10%) to give the title compound as a yellow amorphous solid. 
Yield: 18 mg, 0.057 mmol, 23%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) =  13.45 (s, 1H), 
10.63 (s, 1H), 9.33 (s, 1H), 7.61 (ddd, J = 11.9, 8.2, 1.4 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.19 
(dt, J = 3.8, 1.8 Hz, 1H), 7.01 (dd, J = 8.2, 2.1 Hz, 1H), 6.83 – 6.76 (m, 2H), 6.32 (dt, J = 3.7, 2.4 
 41 
Hz, 1H), 2.99 (q, J = 7.4 Hz, 2H), 1.29 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) 
δC (ppm) = 169.3, 136.1, 131.6, 131.4, 129.4, 128.3, 126.1, 124.9, 120.7, 120.2, 112.1, 111.3, 
109.7, 44.5, 7.8. MS (EI) m/z = 317 [M] +. HPLC (254 nm): tR = 4.965 min (96.3844%). 
(Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)ethenesulfonamide (2i). To a 
solution of (Z)-3-((1H-pyrrol-2-yl)methylene)-5-aminoindolin-2-one (112 mg, 0.5 mmol, 1.0 equiv) 
in THF (5 ml) was added diisopropyl ethyl amine (175 µl, 1.0 mmol, 2.0 equiv) and 2-
chloroethane sulfonylchloride (53 µl, 0.5 mmol, 1.1 equiv). The reaction was stirred overnight at 
room temperature and quenched by the addition of brine (20 ml) and ethyl acetate (20 ml). The 
organic layer was dried over Na2SO4, the solvent was evaporated, and the crude product was 
purified by silica chromatography (dichloromethane/MeOH = 20/1) to give the title compound as 
a yellow amorphous solid. Yield: 57 mg, 0.18 mmol, 36%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) =  13.42 (s, 1H), 10.69 (s, 1H), 7.51 (s, 1H), 7.37 (d, J = 2.0 Hz, 1H), 7.22 (td, J = 2.6, 1.4 
Hz, 1H), 6.96 (dd, J = 8.2, 2.1 Hz, 1H), 6.83 (d, J = 1.9 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.32 
(d, J = 3.7 Hz, 1H), 6.04 (d, J = 16.6 Hz, 1H), 5.90 (d, J = 10.0 Hz, 1H). 13C NMR (126 MHz, 
DMSO-d6) δC (ppm) = 169.3, 136.4, 136.0, 131.0, 129.5, 126.5, 126.3, 125.6, 125.1, 121.5, 
120.4, 116.6, 113.0, 111.3, 109.6. MS (EI) m/z = 315 [M] +. HPLC (254 nm): tR = 5.227 min 
(96.8706%). 
N-(3-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)acetamide (3a). To a solution of N2-(3-aminophenyl)-N4-(5-cyclopropyl-1H-
pyrazol-3-yl)pyrimidine-2,4-diamine (129 mg, 0.42 mmol, 1.0 equiv) in ethyl acetate (15 ml) at 0°C 
was added acetic anhydride (79.4 µl, 0.84 mmol, 2.0 equiv) and the mixture was stirred at room 
temperature overnight. The precipitate was isolated by filtration and dried under high vacuum to 
give the title compound as a yellow amorphous solid. Yield: 78 mg, 0.22 mmol, 52%. 1H NMR 
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(500 MHz, DMSO-d6) δH (ppm) = 11.99 (s, 1H), 9.83 (s, 1H), 9.44 (d, J = 85.0 Hz, 2H), 9.35 – 
8.90 (m, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.95 – 7.72 (m, 1H), 7.59 – 7.38 (m, 1H), 7.30 – 6.94 (m, 
2H), 6.38 (s, 1H), 2.06 (s, 3H), 1.86 (tt, J = 8.4, 5.0 Hz, 1H), 0.91 (dq, J = 6.4, 4.0 Hz, 2H), 0.80 
– 0.63 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 168.09, 159.54, 155.74, 141.09, 
139.35, 128.34, 114.29, 112.32, 110.13, 98.25, 59.72, 23.98, 20.72, 14.06, 8.52, 7.63. MS (ESI): 
m/z = 350.18 [M+H] +. HPLC (254 nm): tR = 1.514 min (95.6875%). 
N-(4-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)acetamid (3b). To a solution of N2-(4-aminophenyl)-N4-(5-cyclopropyl-1H-
pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in dry THF (15 ml) at 0°C 
was added pyridine (58 µl, 0.716 mmol, 1.1 equiv) and acetic acid anhydride (68 µl, 
0.716 mmol, 1.0 equiv) and the solution was stirred at room temperature overnight. The solvent 
was evaporated, and the crude product was purified by silica chromatography 
(dichloromethane/MeOH = 10/1) to give the title compound as  a yellow amorphous solid. Yield: 
124 mg, 0.355 mmol, 55%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 12.05 (s, 1H), 9.78 (s, 
1H), 9.57 (s, 1H), 9.05 (s, 1H), 7.97 (d, J = 5.7 Hz, 1H), 7.72 – 7.59 (m, 2H), 7.55 – 7.42 (m, 
2H), 6.38 (s, 1H), 6.08 (s, 1H), 2.04 (s, 3H), 1.87 (tt, J = 8.4, 5.1 Hz, 1H), 0.98 – 0.82 (m, 2H), 
0.76 – 0.59 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 167.7, 159.6, 159.5, 155.9, 
155.8, 136.2, 133.1, 119.3, 97.8, 59.7, 54.9, 23.8, 21.0, 20.7, 14.1, 7.7. MS (ESI): m/z = 350.18 
[M+H] +. HPLC (254 nm): tR = 1.352 min (98.1651%). 
2-Chloro-N-(3-((4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)acet-amide (3c). To a stirred solution of N2-(3-aminophenyl)-N4-(5-cyclopropyl-
1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF (5 ml) was added 
triethylamine (99 µl, 0.716 mmol, 1.1 equiv) and 2-chloroacetyl chloride (57 µl, 0.716 mmol, 
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1.1 equiv) in THF (2 ml). After one hour additional triethylamine (36 µl, 0.26 mmol, 0.4 equiv) 
and 2-chloroacetyl chloride (21µl, 0.26 mmol, 0.4 equiv) was added and the solution was stirred 
overnight. Saturated aqueous sodium hydrogen carbonate solution (15 ml) and brine (15 ml) 
were added and the mixture was extracted with ethyl acetate (40 ml). The organic layer was 
dried over Na2SO4, the solvent was removed, and the residue was purified by silica 
chromatography (dichloromethane/MeOH = 10/1) to give the title compound as a yellow 
amorphous solid. Yield: 100 mg, 0.261 mmol, 40%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) =  
11.97 (s, 1H), 10.21 (s, 1H), 9.48 (s, 1H), 9.09 (s, 1H), 7.93 (d, J = 71.4 Hz, 2H), 7.55 (d, J = 8.0 
Hz, 1H), 7.23 (q, J = 11.5, 8.0 Hz, 2H), 6.38 (d, J = 67.1 Hz, 2H), 4.27 (s, 2H), 1.87 (tt, J = 8.5, 
5.1 Hz, 1H), 0.92 (s, 2H), 0.78 – 0.58 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 
164.4, 159.5, 155.6, 148.2, 145.4, 141.3, 138.5, 128.5, 115.2, 112.5, 110.6, 98.4, 93.0, 43.6, 7.6, 
6.9. MS (ESI): m/z = 384.14 [M+H] +. HPLC (254 nm): tR = 2.180 min (97.3103%). 
2-Chloro-N-(4-((4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)acet-amide (3d). To a stirred solution of N2-(4-aminophenyl)-N4-(5-cyclopropyl-
1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF (15 ml) was 
added triethylamine (99 µl, 0.716 mmol, 1.1 equiv) and 2-chloroacetyl chloride (57 µl, 
0.716 mmol, 1.1 equiv) and the solution was stirred overnight. Saturated aqueous sodium 
hydrogen carbonate solution (15 ml) and brine (15 ml) were added and the mixture was extracted 
with ethyl acetate (40 ml). The organic phase was dried with sodium sulfate, the solvent was 
removed, and the residue was purified by silica chromatography (dichloromethane/MeOH = 
10/1) to give the title compound as a yellow amorphous solid. Yield: 95 mg, 0.248 mmol, 38%. 
1H NMR (500 MHz, DMSO-d6) δH (ppm) =  12.00 (s, 1H), 10.18 (s, 1H), 9.49 (s, 1H), 9.04 (s, 
1H), 8.11 – 7.85 (m, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.56 – 7.47 (m, 2H), 6.47 (d, J = 25.5 Hz, 
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1H), 6.33 – 6.11 (m, 1H), 4.24 (s, 2H), 1.87 (tt, J = 8.5, 5.1 Hz, 1H), 0.93 (d, J = 8.2 Hz, 2H), 
0.69 (tt, J = 6.9, 4.4 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 164.0, 159.4, 155.6, 
136.96, 132.0, 119.7, 97.9, 43.6, 7.7. MS (ESI): m/z = 384.14 [M+H] +. HPLC (254 nm): tR = 
1.949 min (97.8748%). 
N-(3-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)propionamide (3e). To a solution of N2-(3-aminophenyl)-N4-(5-cyclopropyl-1H-
pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in dry THF (15 ml) was 
added pyridine (63 µl, 0.781 mmol, 1.2 equiv) and propionic acid anhydride (100 µl, 
0.781 mmol, 1.2 equiv) and the solution was stirred at room temperature overnight. The solvent 
was evaporated, the residue was dissolved in ethyl acetate and washed with water (30 ml). The 
organic extract was dried over Na2SO4 and the solvent was removed. The crude product was 
purified by flash chromatography (dichloromethane/MeOH = 0 to 10%) to yield the product as a 
yellow amorphous solid. Yield: 111 mg, 0.305 mmol, 47%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) =  11.97 (s, 1H), 9.76 (s, 1H), 9.49 (s, 1H), 9.04 (s, 1H), 8.00 (d, J = 5.6 Hz, 1H), 7.86 (s, 
1H), 7.59 – 7.38 (m, 1H), 7.26 (d, J = 8.2 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 6.37 (s, 2H), 2.34 (q, 
J = 7.6 Hz, 2H), 1.86 (tt, J = 8.4, 5.0 Hz, 1H), 1.10 (t, J = 7.5 Hz, 3H), 0.91 (d, J = 8.1 Hz, 2H), 
0.74 – 0.64 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 171.8, 155.6, 141.1, 139.4, 
128.3, 112.4, 98.2, 54.9, 40.0, 39.9, 39.7, 39.5, 39.4, 39.2, 39.0, 29.5, 9.7, 7.6. MS (ESI): m/z = 
364.19 [M+H] +. HPLC (254 nm): tR = 1.922 min (96.0849%). 
N-(4-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)propionamide (3f). To a solution of N2-(4-aminophenyl)-N4-(5-cyclopropyl-1H-
pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1 equiv) in dry THF (15 ml) was added 
pyridine (58 µl, 0.716 mmol, 1.1 equiv) and propionic acid anhydride (91 µl, 0.716 mmol, 
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1.1 equiv) and the solution was stirred at room temperature overnight. The solvent was 
evaporated, and the residue was dissolved in ethyl acetate and washed with water (30 ml). The 
organic extract was dried over Na2SO4 and the solvent was removed. The crude product was 
purified by flash chromatography (dichloromethane/MeOH = 0 to 10%) to yield the product as a 
yellow amorphous solid. Yield: 104 mg, 0.286 mmol, 40%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) = 12.17 (s, 1H), 10.00 (d, J = 15.7 Hz, 1H), 9.82 (s, 1H), 9.41 (s, 1H), 7.95 (d, J = 6.2 Hz, 
1H), 7.57 (s, 4H), 6.42 (s, 1H), 6.05 (s, 1H), 2.33 (q, J = 7.6 Hz, 2H), 1.86 (tt, J = 8.4, 5.0 Hz, 
1H), 1.11 (t, J = 7.6 Hz, 3H), 0.99 – 0.86 (m, 2H), 0.65 (dt, J = 6.6, 3.2 Hz, 2H). 13C NMR (126 
MHz, DMSO-d6) δC (ppm) = 171.5, 159.5, 157.7, 134.4, 120.9, 119.3, 98.1, 51.4, 29.5, 28.7, 
28.5, 28.4, 9.8, 7.7, 7.1. MS (ESI): m/z = 364.20 [M+H] +. HPLC (254 nm): tR = 1.674 min 
(95.2979%). 
N-(3-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)acrylamide (3g). To a stirred solution of N2-(3-aminophenyl)-N4-(5-cyclopropyl-
1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF (15 ml) was 
added pyridine (58 µl, 0.716 mmol, 1.1 equiv) and acryloyl chloride (59 µl, 0.716 mmol, 
1.1 equiv) and the solution was stirred for one hour at 0°C and at room temperature overnight. 
The solvent was evaporated, and the residue was taken up in ethyl acetate and washed with 
saturated aqueous sodium hydrogen carbonate solution (15 ml) and brine (15 ml). The organic 
layer was dried over Na2SO4, the solvent was removed, and the residue was purified by silica 
chromatography (dichloromethane/MeOH = 10/1) to give the title compound as a colorless 
amorphous solid. Yield: 62 mg, 0.171 mmol, 26%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 
11.97 (s, 1H), 10.06 (s, 1H), 9.46 (d, J = 68.4 Hz, 1H), 9.35 – 9.00 (m, 1H), 8.10 – 7.88 (m, 3H), 
7.50 (dd, J = 8.2, 2.0 Hz, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 8.1 Hz, 1H), 6.50 (dd, J = 
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17.0, 10.2 Hz, 1H), 6.27 (dd, J = 16.9, 2.0 Hz, 1H), 5.75 (dd, J = 10.2, 2.1 Hz, 1H), 1.86 (tt, J = 
8.4, 5.1 Hz, 1H), 0.90 (tt, J = 9.3, 5.4 Hz, 2H), 0.78 – 0.59 (m, 2H). 13C NMR (126 MHz, 
DMSO-d6) δC (ppm) = 163.0, 159.4, 141.1, 139.1, 132.1, 128.5, 126.5, 112.7, 98.3, 7.6. MS 
(ESI): m/z = 362.18 [M+H] +. HPLC (254 nm): tR = 1.933 min (95.0714%). 
N-(4-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)acrylamide (3h). To a stirred solution of N2-(4-aminophenyl)-N4-(5-cyclopropyl-
1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF (15 ml) was 
added pyridine (58 µl, 0.716 mmol, 1.1 equiv) and acryloyl chloride (59 µl, 0.716 mmol, 
1.1 equiv) and the solution was stirred for one hour at 0°C. The solvent was removed, and the 
residue was purified by silica chromatography (dichloromethane/MeOH = 10/1) to give the title 
compound as a colorless amorphous solid. Yield: 30 mg, 0.083 mmol, 13%. 1H NMR (500 MHz, 
DMSO-d6) δH (ppm) =  11.99 (s, 1H), 10.02 (s, 1H), 9.47 (s, 1H), 9.00 (s, 1H), 7.98 (d, J = 5.8 
Hz, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.64 – 7.53 (m, 2H), 6.45 (dd, J = 16.9, 10.2 Hz, 1H), 6.25 
(dd, J = 17.0, 2.1 Hz, 1H), 5.73 (dd, J = 10.2, 2.0 Hz, 1H), 1.87 (tt, J = 8.4, 5.0 Hz, 1H), 0.99 – 
0.86 (m, 2H), 0.76 – 0.63 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 162.6, 159.5, 
155.9, 136.7, 132.6, 132.1, 126.1, 119.6, 119.3, 97.9, 14.1, 7.7. MS (ESI): m/z = 362.18 [M+H] 
+. HPLC (254 nm): tR = 1.703 min (96.9724%). 
N-(3-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)propiolamide (3i). To a stirred solution of N2-(3-aminophenyl)-N4-(5-
cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in DMF 
(5 ml) at 0°C was added diisopropylethylamine (233 µl, 1.37 mmol, 2.1 equiv), propargylic acid 
(241 µl, 3.9 mmol, 6.0 equiv) and N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide 
hydrochloride (263 mg, 1.37 mmol, 2.1 equiv) and the solution was stirred for two hours at 0°C. 
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The reaction mixture was diluted with ethyl acetate and the solvent was removed by freeze 
drying. The residue was purified by silica chromatography (dichloromethane/MeOH = 10/1) to 
give the title compound as a colorless amorphous solid. Yield: 12 mg, 0.033 mmol, 5%. 1H NMR 
(500 MHz, DMSO-d6) δH (ppm) =  11.99 (s, 1H), 9.47 (s, 1H), 9.05 (s, 1H), 7.97 (s, 2H), 7.70 (d, 
J = 8.6 Hz, 2H), 7.55 – 7.45 (m, 2H), 6.56 – 6.08 (m, 2H), 4.34 (s, 1H), 1.87 (tt, J = 8.5, 5.1 Hz, 
1H), 0.93 (d, J = 8.1 Hz, 2H), 0.74 – 0.65 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 
159.9, 157.1, 153.5, 146.7, 135.0, 129.3, 117.6, 116.7, 116.7, 95.5, 76.2, 74.2, 5.3. MS (ESI): 
m/z = 360.15 [M+H] +. HPLC (254 nm): tR = 1.854 min (97.5080%). 
N-(4-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)propiolamide (3j). To a stirred solution of N2-(4-aminophenyl)-N4-(5-
cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (130 mg, 0.42 mmol, 1.0 equiv) in DMF 
(10 ml) at 0°C was added diisopropylethylamine (150 µl, 0.882 mmol, 2.1 equiv), propargylic 
acid (150 µl, 2.52 mmol, 6.0 equiv) and N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide 
hydrochloride (169 mg, 0.882 mmol, 2.1 equiv) and the solution was stirred for two hours at 
0°C. The reaction mixture was diluted with ethyl acetate and washed with 0.1 N HCl (20 ml) and 
0.1 N NaOH (20 ml) and the organic layer was dried with sodium sulfate and the solvent 
removed by freeze-drying. The residue was purified by silica chromatography (DCM/MeOH = 
10/1) to give the title compound as a colorless amorphous solid. Yield: 26 mg, 0.072 mmol, 
17%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) =  11.97 (s, 1H), 10.71 (s, 1H), 9.49 (s, 1H), 9.06 
(d, J = 39.8 Hz, 1H), 7.95 (d, J = 39.2 Hz, 2H), 7.56 (s, 1H), 7.21 (d, J = 5.1 Hz, 2H), 6.56 – 6.16 
(m, 2H), 4.37 (s, 1H), 1.86 (tt, J = 8.4, 5.0 Hz, 1H), 0.96 – 0.85 (m, 2H), 0.74 – 0.64 (m, 2H). 13C 
NMR (126 MHz, DMSO-d6) δC (ppm) = 159.5, 155.5, 149.5, 141.2, 138.2, 128.5, 113.0, 98.3, 
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78.5, 76.8, 56.0, 18.5, 7.6. MS (ESI): m/z = 360.16 [M+H] +. HPLC (254 nm): tR = 1.692 min 
(99.0749%). 
N-(3-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)ethanesulfon-amide (3k). To a solution of N2-(3-aminophenyl)-N4-(5-
cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF 
(10 ml) was added triethylamine (180 µl, 1.3 mmol, 2.0 equiv) and ethane sulfonyl chloride (123 
µl, 1.3 mmol, 2.0 equiv) and the mixture was stirred at room temperature for 1 h and at 60°C for 
1 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed 
with brine and saturated aqueous sodium bicarbonate solution. The organic layer was dried over 
Na2SO4, the solvent was removed, and the residue was purified by silica chromatography 
(dichloromethane/MeOH = 10/1) to give the title compound as a yellow amorphous solid. Yield: 
81 mg, 0.203 mmol, 31%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 11.98 (s, 1H), 9.63 (s, 
1H), 9.41 (s, 1H), 9.08 (s, 1H), 7.98 (s, 1H), 7.69 – 7.44 (m, 2H), 7.20 (t, J = 8.1 Hz, 1H), 6.86 – 
6.74 (m, 1H), 6.46 (s, 1H), 6.30 (s, 1H), 3.12 (q, J = 7.3 Hz, 2H), 1.94 – 1.84 (m, 1H), 1.23 (t, J 
= 7.4 Hz, 3H), 0.98 – 0.85 (m, 2H), 0.71 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 
159.7, 159.5, 155.8, 148.1, 145.4, 141.8, 138.5, 128.9, 114.8, 112.4, 110.6, 98.4, 93.05, 54.9, 
45.0, 7.99, 7.7, 6.8. MS (ESI): m/z = 400.16 [M+H] +. HPLC (254 nm): tR = 2.142 min 
(96.4205%). 
N-(4-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)ethanesulfon-amide (3l). To a solution of N2-(4-aminophenyl)-N4-(5-
cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF 
(10 ml) was added triethylamine (180 µl, 1.3 mmol, 2.0 equiv) and ethane sulfonyl chloride (123 
µl, 1.3 mmol, 2.0 equiv) and the mixture was stirred at room temperature for 1 h and at 60°C for 
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1 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed 
with brine and saturated aqueous sodium bicarbonate solution. The organic layer was dried over 
Na2SO4, the solvent was removed, and the residue was purified by silica chromatography 
(dichloromethane/MeOH = 10/1) to give the title compound as a yellow amorphous solid. Yield: 
102 mg, 0.256 mmol, 39%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 11.99 (s, 1H), 9.46 (s, 
2H), 9.02 (s, 1H), 8.13 – 7.91 (m, 1H), 7.71 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 6.49 (d, 
J = 39.7 Hz, 1H), 6.22 (s, 1H), 3.03 (q, J = 7.3 Hz, 2H), 1.88 (dq, J = 8.8, 5.0, 4.3 Hz, 1H), 1.23 
(t, J = 7.3 Hz, 3H), 1.00 – 0.86 (m, 2H), 0.77 – 0.64 (m, 2H). 13C NMR (126 MHz, DMSO-d6) 
δC (ppm) = 159.5, 155.9, 148.1, 145.5, 137.7, 131.2, 121.3, 119.8, 98.0, 93.0, 54.9, 44.6, 8.0, 7.7, 
6.8. MS (ESI): m/z = 400.16 [M+H] +. HPLC (254 nm): tR = 1.966 min (95.4217%). 
N-(3-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)ethenesulfon-amide (3m). To a stirred solution of N2-(3-aminophenyl)-N4-(5-
cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 0.651 mmol, 1.0 equiv) in THF 
(10 ml) was added triethylamine (90 µl, 0.65 mmol, 1.0 equiv) and 2-chloroethanesulfonyl 
chloride (68 µl, 0.651 mmol, 1.0 equiv) and the solution was stirred for one hour at 0°C. 
Additional triethylamine (90 µl, 0.65 mmol, 1.0 equiv) was added and the mixture was stirred at 
room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed 
with saturated aqueous sodium bicarbonate solution (15 ml) and brine (15 ml). The organic layer 
was dried over Na2SO4, the solvent was removed, and the residue was purified by flash 
chromatography (dichloromethane/MeOH = 100/1 to 10/1) to give the title compound as a 
yellow amorphous solid. Yield: 40 mg, 0.1 mmol, 15%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) = 11.98 (s, 1H), 9.88 (d, J = 45.6 Hz, 1H), 9.50 (d, J = 85.1 Hz, 1H), 9.08 (s, 1H), 8.13 – 
7.93 (m, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.16 (t, J = 7.7 Hz, 1H), 6.84 – 6.77 (m, 1H), 6.76 – 6.71 
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(m, 1H), 6.47 (s, 1H), 6.30 (s, 1H), 6.18 (d, J = 16.4 Hz, 1H), 6.06 (d, J = 9.9 Hz, 1H), 1.88 (s, 
1H), 0.94 (d, J = 8.2 Hz, 2H), 0.70 (t, J = 13.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) 
δC (ppm) = 161.0, 156.9, 149.4, 146.7, 143.0, 139.1, 137.6, 130.0, 128.8, 116.1, 113.7, 112.0, 
99.8, 94.4, 56.2, 9.0, 8.1. MS (ESI): m/z = 398.15 [M+H] +. HPLC (254 nm): tR = 2.261 min 
(97.3760%). 
N-(4-((4-((5-Cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-
yl)amino)phenyl)ethenesulfon-amide (3n). To a stirred solution of N2-(4-aminophenyl)-N4-(5-
cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (220 mg, 0.72 mmol, 1.0 equiv) in THF 
(10 ml) at 0°C was added triethylamine (119 µl, 0.86 mmol, 1.2 equiv) and 2-
chloroethanesulfonyl chloride (90 µl, 0.86 mmol, 1.2 equiv) and the solution was stirred at room 
temperature overnight. Additional triethylamine (198 µl, 1.43 mmol, 2.0 equiv) and 2-
chloroethanesulfonyl chloride (75 µl, 0.72 mmol, 1.0 equiv) were added and the mixture was 
stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and 
washed with saturated aqueous sodium hydrogen carbonate solution (15 ml) and brine (15 ml). 
The organic phase was dried over Na2SO4, the solvent was removed, and the residue was 
purified by silica chromatography (dichloromethane/MeOH = 10/1) to give the title compound as 
a yellow amorphous solid. Yield: 24 mg, 0.06 mmol, 9%. 1H NMR (500 MHz, CD3OD) δH 
(ppm) = 7.82 (d, J = 6.0 Hz, 1H), 7.52 – 7.39 (m, 2H), 7.09 – 7.00 (m, 2H), 6.56 (dd, J = 16.5, 
10.0 Hz, 1H), 6.17 (s, 1H), 6.02 (s, 1H), 5.83 (d, J = 9.9 Hz, 1H), 1.79 (tt, J = 8.5, 5.1 Hz, 1H), 
0.91 – 0.76 (m, 2H), 0.61 (dq, J = 9.0, 3.4, 2.6 Hz, 2H). 13C NMR (126 MHz, CD3OD) δC (ppm) 
= 161.2, 156.9, 139.0, 137.2, 132.9, 127.7, 123.7, 123.0, 122.0, 117.4, 99.0, 8.3. MS (ESI): m/z 
= 398.15 [M+H] +. HPLC (254 nm): tR = 2.131 min (97.6470%). 
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(Z)-5-((5-(2-Chloroacetamido)-2-oxoindolin-3-ylidene)methyl)-N-(2-
(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (4a). To a solution of (Z)-5-
((5-amino-2-oxoindolin-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-
3-carboxamide (37 mg, 0.093 mmol, 1.0 equiv) in dry THF (5 ml) at 0°C was added diisopropyl 
ethylamine (32 µl, 0.186 mmol, 2.0 equiv) and  2-chloro acetyl chloride (8.9 µl, 0.11 mmol, 
1.2 equiv). The reaction mixture was stirred for 18 h and quenched with brine (30 ml) and ethyl 
acetate (30 ml) and extracted with ethyl acetate (2 x 30 ml). The organic layers were combined, 
dried over Na2SO4 and the solvent was evaporated. The crude product was purified by reversed-
phase flash chromatography (acetonitrile/H2O = 10 to 100%) to give the title compound as a 
yellow amorphous solid. Yield: 17 mg, 0.036 mmol, 39%. 1H NMR (500 MHz, DMSO-d6) δH 
(ppm) = 13.60 (s, 1H), 10.83 (s, 1H), 10.12 (s, 1H), 7.84 (s, 1H), 7.46 (s, 1H), 7.38 (t, J = 5.6 Hz, 
1H), 7.23 (d, J = 8.5 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 4.21 (s, 2H), 2.55 – 2.43 (m, 8H), 2.41 (s, 
3H), 2.37 (s, 3H), 0.95 (t, J = 7.1 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 169.5, 
164.5, 164.3, 135.9, 135.1, 132.3, 129.3, 125.6, 125.6, 123.3, 119.0, 111.1, 109.4, 51.7, 46.5, 
43.5, 37.0, 13.3, 11.8, 10.5. MS (ESI) m/z = 472.2 [M+H] +. HPLC (254 nm): tR = 2.872 min 
(100.0000%). 
(Z)-N-(2-(Diethylamino)ethyl)-2,4-dimethyl-5-((2-oxo-5-(vinylsulfonamido)indolin-3-
ylidene)-methyl)-1H-pyrrole-3-carboxamide (4b). To a solution of (Z)-5-((5-amino-2-
oxoindolin-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-3-
carboxamide (68 mg, 0.17 mmol, 1.0 equiv) in dry THF (10 ml) at 0°C was added triethylamine 
(46 µl, 0.34 mmol, 2.0 equiv) and  2-chloroethanesulfonyl chloride (36 µl, 0.34 mmol, 
2.0 equiv). The reaction mixture was stirred for 18 h and quenched with brine (20 ml) and ethyl 
acetate (20 ml) and extracted with ethyl acetate (2 x 20 ml). The organic layers were combined, 
 52 
dried over Na2SO4 and the solvent was evaporated. The crude product was purified by reversed-
phase flash chromatography (acetonitrile/H2O = 10 to 100%) to give the title compound as a 
yellow amorphous solid. Yield: 34 mg, 0.07 mmol, 41%. 1H-NMR (500 MHz, CDCl3 / DMSO-
d6 = 8/1) δH (ppm) = 13.35 (s, 1H), 10.02 (s, 1H), 7.08 (d, J = 2.0 Hz, 1H), 7.04 (s, 1H), 6.71 (dd, 
J = 8.3, 2.1 Hz, 1H), 6.51 (dd, J = 11.5, 7.0 Hz, 2H), 6.31 (dd, J = 16.6, 10.0 Hz, 1H), 5.83 (d, J = 
16.7 Hz, 1H), 5.59 (d, J = 10.0 Hz, 1H), 3.23 – 3.18 (m, 2H), 2.45 (t, J = 6.1 Hz, 2H), 2.41 – 2.35 
(m, 4H), 2.25 (s, 3H), 2.17 (s, 3H), 0.79 (d, J = 7.1 Hz, 6H). 13C NMR (126 MHz, CDCl3 / 
DMSO-d6 = 8/1) δC (ppm) = 170.0, 165.5, 137.1, 136.20 135.6, 130.8, 128.9, 126.4, 126.3, 
126.0, 123.0, 121.6, 119.2, 115.2, 113.2, 109.7, 51.4, 46.4, 36.5, 13.8, 11.3, 11.1. MS (ESI) m/z 
= 486.2 [M+H] +. HPLC (254 nm): tR = 2.862 min (96.1594%). 
(Z)-5-((5-Acetamido-2-oxoindolin-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2,4-
dimethyl-1H-pyrrole-3-carboxamide (4c). To a solution of (Z)-5-((5-amino-2-oxoindolin-3-
ylidene)methyl)-N-(2-(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (71 mg, 
0.18 mmol, 1.0 equiv) in dry THF (10 ml) at 0°C was added triethylamine (50 µl, 0.36 mmol, 2 
eq.) and acetyl chloride (26 µl, 0.36 mmol, 2.0 equiv). The reaction mixture was stirred for 18 h 
at room temperature and then quenched with brine (30 ml) and ethyl acetate (30 ml) and 
extracted with ethyl acetate (2 x 30 ml). The organic layers were combined, dried over Na2SO4 
and the solvent was evaporated. The crude product was purified by reversed-phase flash 
chromatography (acetonitrile/H2O = 10 to 100%) to give the title compound as a yellow 
amorphous solid. Yield: 48 mg, 0.11 mmol, 61%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 
13.64 (s, 1H), 10.81 (s, 1H), 9.77 (s, 1H), 8.05 (t, J = 5.4 Hz, 1H), 7.83 (d, J = 2.1 Hz, 1H), 7.67 
(s, 1H), 7.54 (t, J = 5.3 Hz, 1H), 7.44 (s, 1H), 7.27 (dd, J = 8.3, 2.0 Hz, 1H), 7.07 (d, J = 4.0 Hz, 
1H), 6.83 (d, J = 8.3 Hz, 1H), 6.37 (d, J = 4.1 Hz, 1H), 6.28 (s, 1H), 3.30 – 3.25 (m, 1H), 3.12 (t, 
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J = 7.7 Hz, 2H), 2.48 (s, 3H), 2.46 (s, 3H), 2.40 (s, 3H), 2.26 (s, 3H), 2.04 (s, 3H). 13C NMR 
(126 MHz, DMSO-d6) δC (ppm) = 169.5, 167.8, 164.5, 135.7, 134.5, 133.3, 128.9, 125.5, 125.4, 
122.8, 120.5, 118.7, 115.2, 110.7, 109.3, 51.7, 46.5, 37.0, 23.7, 13.3, 11.9, 10.4. . MS (ESI) m/z 
= 438.3 [M+H] +. HPLC (254 nm): tR = 1.823 min (95.7322%). 
(Z)-N-(2-(Diethylamino)ethyl)-5-((5-(ethylsulfonamido)-2-oxoindolin-3-
ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (4d). To a solution of (Z)-5-((5-
amino-2-oxoindolin-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-3-
carboxamide (100 mg, 0.25 mmol, 1.0 equiv) in dry DMF (2 ml) was added pyridine (20 µl, 
0.25 mmol, 1 eq.) and  ethane sulfonyl chloride (24 µl, 0.25 mmol, 1.0 equiv). The reaction 
mixture was stirred for 18 h at room temperature and then quenched with brine (20 ml) and ethyl 
acetate (30 ml) and washed with brine (5 x 30 ml). The organic layer was dried over Na2SO4 and 
the solvent was evaporated. The crude product was purified by reversed-phase flash 
chromatography (acetonitrile/H2O = 10 to 100%) to give the title compound as a yellow 
amorphous solid. Yield: 39 mg, 0. 08 mmol, 32 %. 1H NMR (500 MHz, CDCl3 / DMSO- d6 = 
8/1) δH (ppm) = 13.37 (s, 1H), 9.83 (s, 1H), 8.72 (s, 1H), 7.58 (t, J = 5.7 Hz, 1H), 7.22 (s, 1H), 
7.12 (s, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H), 3.69 (q, J = 5.7 Hz, 2H), 3.24 (t, J 
= 5.7 Hz, 2H), 3.12 (q, J = 7.4 Hz, 4H), 2.93 (t, J = 7.3 Hz, 2H), 2.35 (s, 3H), 2.28 (s, 3H), 1.33 – 
1.17 (m, 9H). 13C NMR (126 MHz, CDCl3 / DMSO- d6 = 8/1) δC (ppm) = 167.0, 141.4, 137.6, 
136.0, 131.5, 129.8, 126.6, 126.2, 123.2, 120.9, 118.3, 115.4, 112.6, 110.0, 52.0, 48.0, 45.0, 35.3, 
13.8, 10.9, 8.6, 8.0. MS (ESI) m/z = 488.24 [M+H] +. HPLC (254 nm): tR = 2.555 min 
(95.5186%). 
(Z)-N-(2-(2-(4-(2,8-Diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-10-yl)phenoxy)acetamido)ethyl)-2,4-dimethyl-5-((2-oxo-5-
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(vinylsulfon-amido)indolin-3-ylidene)methyl)-1H-pyrrole-3-carboxamide (5a) To a solution 
of (Z)-N-(2-(2-(4-(2,8-diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)phenoxy)acetamido)ethyl)-2,4-dimethyl-5-((2-oxo-5-(2,2,2-trifluoro-
acetamido)indolin-3-ylidene)methyl)-1H-pyrrole-3-carboxamide (56 mg, 0.064 mmol, 1.0 equiv) 
in water (6 ml) and MeOH (8 ml) was added potassium carbonate (25 mg, 0.179 mmol, 
2.8 equiv) and the reaction mixture was stirred at room temperature for 18 h. Then, saturated 
sodium bicarbonate solution (20 ml) and dichloromethane (20 ml) were added, and the aqueous 
layer was extracted with dichloromethane (2 x 20 ml). The combined organic layers were 
washed with brine (3 x 50 ml), dried over MgSO4 and filtered. The resulting solution was cooled 
to 0°C and 2-chloroethane sulfonyl chloride (10 µl, 0.1 mmol, 1.5 equiv) and triethylamine 
(18 µl, 0.13 mmol, 2.0 equiv) was added and the reaction mixture was stirred for 18 h at room 
temperature. The reaction was quenched with saturated aq. sodium bicarbonate solution (20 ml) 
and washed with brine (3 x 20 ml). The organic layer was dried over magnesium sulfate and the 
solvent was removed. The crude product was purified by silica chromatography 
(dichloromethane/MeOH = 20/1 to 10/1) to give the title compound as a red amorphous solid. 
Yield: 28 mg, 0.032 mmol, 51%. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 13.68 (s, 1H), 
10.89 (s, 1H), 9.54 (s, 1H), 8.31 (dd, J = 11.6, 6.1 Hz, 1H), 7.71 (d, J = 5.3 Hz, 1H), 7.55 (d, J = 
3.6 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 6.96 (dd, J = 8.2, 2.0 Hz, 1H), 
6.84 (d, J = 8.2 Hz, 1H), 6.78 (dd, J = 16.4, 10.0 Hz, 1H), 6.06 – 5.96 (m, 2H), 4.59 (s, 2H), 3.37 
(s, 5H), 2.46 (s, 3H), 2.44 (s, 7H), 2.43 (s, 3H), 2.31 (q, J = 7.5 Hz, 5H), 1.32 (s, 6H), 0.95 (t, J = 
7.5 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δC (ppm) = 169.5, 167.6, 165.1, 158.1, 153.0, 
140.5, 138.1, 136.4, 136.1, 136.1, 136.0, 132.5, 130.9, 130.3, 129.8, 129.3, 127.4, 126.8, 126.0, 
125.6, 123.7, 121.9, 120.5, 115.5, 114.7, 114.2, 109.6, 67.1, 38.7, 38.5, 16.4, 14.5, 13.3, 12.2, 
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11.5, 10.5. 11B NMR (160 MHz, DMSO-d6) δB (ppm)  = 3.79 (t, J = 34.2 Hz) ppm. 19F NMR 
(471 MHz, DMSO-d6) δF (ppm) = -142.99 (dd, J = 66.5, 29.5 Hz) ppm. MS (APCI) m/z = 
846.36 [M-F] +. HPLC (360 nm): tR = 8.685 min (95.2191%). 
(Z)-5-((5-(2-Chloroacetamido)-2-oxoindolin-3-ylidene)methyl)-N-(2-(3-(5,5-difluoro-
7,9-dimethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)propanamido)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (5b). To a solution of (Z)-N-
(2-(3-(5,5-difluoro-7,9-dimethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)propanamido)ethyl)-2,4-dimethyl-5-((2-oxo-5-(2,2,2-trifluoroacetamido)indolin-3-
ylidene)methyl)-1H-pyrrole-3-carboxamide (26 mg, 0.037 mmol, 1.0 equiv) in water (7 ml) and 
MeOH (15 ml) was added potassium carbonate (10.2 mg, 0.074 mmol, 2.0 equiv) and the 
reaction mixture was stirred at room temperature for 18 h. Then, saturated aq. sodium 
bicarbonate solution (30 ml) and dichloromethane (30 ml) were added, and the aqueous layer 
was extracted with dichloromethane (2 x 30 ml). The combined organic extracts were washed 
with brine (3 x 50 ml), dried over MgSO4 and filtered. The solution was cooled to 0°C and 2-
chloro acetyl chloride (4.4 µl, 0.056 mmol, 1.5 equiv) and triethylamine (10.2 µl, 0.074 mmol, 
2.0 equiv) was added and the reaction mixture was stirred for 18 h at room temperature. The 
reaction was quenched with saturated aq. sodium bicarbonate solution (20 ml) and washed with 
brine (3 x 20 ml). The organic layer was dried over magnesium sulfate and the solvent was 
removed. The crude product was purified by silica chromatography (dichloromethane/MeOH = 
20/1) to give the title compound as a red amorphous solid. Yield: 7.6 mg, 0.011 mmol, 30%. 1H 
NMR (500 MHz, DMSO-d6) δH (ppm) = 13.65 (s, 1H), 10.87 (s, 1H), 10.14 (s, 1H), 8.06 (t, J = 
5.5 Hz, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.66 (s, 1H), 7.55 (t, J = 5.4 Hz, 1H), 7.49 (s, 1H), 7.30 
(dd, J = 8.3, 2.0 Hz, 1H), 7.06 (d, J = 4.0 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.37 (d, J = 4.0 Hz, 
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1H), 6.27 (s, 1H), 4.26 (s, 2H), 3.37 – 3.34 (m, 2H), 3.30 – 3.25 (m, 4H), 3.12 (t, J = 7.7 Hz, 
2H), 2.48 (s, 3H), 2.46 (s, 3H), 2.41 (s, 3H), 2.26 (s, 3H). 13C NMR (126 MHz, DMSO-d6) 
δC (ppm) = 171.2, 169.5, 164.9, 164.3, 159.1, 157.7, 144.0, 136.1, 135.1, 134.4, 133.0, 132.3, 
129.4, 128.8, 125.6, 125.2, 123.2, 120.4, 120.2, 118.9, 116.5, 114.9, 111.0, 109.4, 43.5, 38.8, 
38.5, 33.8, 24.0, 14.5, 13.3, 10.9, 10.5. MS (ESI) m/z = 712.3 [M+H] +. HPLC (360 nm): tR = 
5.183 min (96.1730%). 
(Z)-N-(2-(2-(4-(2,8-Diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)phenoxy)acetamido)ethyl)-2,4-dimethyl-5-
((2-oxo-5-(2,2,2-trifluoro-acetamido)indolin-3-ylidene)methyl)-1H-pyrrole-3-carboxamide 
(5c) To a solution of 2-(4-(2,8-diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]-diazaborinin-10-yl)phenoxy)acetic acid (45 mg, 0.1 mmol, 
1.0 equiv) in DMF was added  1-hydroxybenzotriazole hydrate (15 mg, 0.11 mmol, 1.1 equiv) 
and N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (20 mg, 0.1 mmol, 
1.0 equiv) and the mixture was stirred for 30 min at room temperature. Then, a mixture of 
triethylamine (42 µl, 0.3 mmol, 3.0 equiv) and (Z)-N-(2-aminoethyl)-2,4-dimethyl-5-((2-oxo-5-
(2,2,2-trifluoroacetamido)-indolin-3-ylidene)methyl)-1H-pyrrole-3-carboxamide hydrochloride 
(47 mg, 0.1 mmol, 1.0 equiv) was added and the reaction mixture was stirred for 18 h at room 
temperature. The reaction mixture was diluted with ethyl acetate (30 ml) and washed with 0.1 N 
hydrochloric acid, 0.1 N aq. sodium hydroxide solution and brine (each 3 x 30 ml). The 
combined organic extracts were dried over Na2SO4, the solvent was evaporated, and the crude 
product was purified by silica chromatography (dichloromethane/MeOH = 20/1) to give the title 
compound as a red amorphous solid. Yield: 56 mg, 0.064 mmol, 64%. 1H NMR (500 MHz, 
DMSO-d6) δH (ppm) = 13.65 (s, 1H), 11.12 (s, 1H), 10.96 (s, 1H), 8.30 (q, J = 7.5, 6.4 Hz, 1H), 
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7.95 (d, J = 2.0 Hz, 1H), 7.74 – 7.67 (m, 1H), 7.59 (s, 1H), 7.33 (dd, J = 8.3, 2.1 Hz, 1H), 7.32 – 
7.24 (m, 2H), 7.22 – 7.15 (m, 2H), 6.93 (d, J = 8.3 Hz, 1H), 4.59 (s, 2H), 3.34 (s, 3H), 2.47 (s, 
3H), 2.44 (d, J = 1.8 Hz, 8H), 2.30 (q, J = 7.4 Hz, 4H), 1.32 (s, 6H), 0.95 (t, J = 7.6 Hz, 6H). 
13C NMR (126 MHz, DMSO-d6) δC (ppm) = 169.6, 167.6, 165.1, 158.1, 154.6, 152.9, 140.5, 
138.1, 136.3, 132.5, 130.3, 129.9, 129.7, 129.3, 127.4, 125.8, 125.7, 123.8, 120.7, 120.5, 117.2, 
115.5, 114.9, 114.6, 113.0, 109.5, 67.1, 38.7, 38.5, 16.4, 14.5, 13.3, 12.2, 11.5, 10.4. 
11B NMR (160 MHz, DMSO-d6) δB (ppm) = 3.69 (t, J = 33.6 Hz). 19F NMR (471 MHz, DMSO-
d6) δF (ppm) = -73.89, -143.02 (dd, J = 65.7, 28.2 Hz) ppm. MS (ESI) m/z = 852.37 [M-F] +. 
HPLC (360 nm): tR = 8.955 min (95.3825%). 
(Z)-5-((5-(Acetamido)-2-oxoindolin-3-ylidene)methyl)-N-(2-(3-(5,5-difluoro-7,9-
dimethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxamide (5d). To a solution of (Z)-N-(2-(3-(5,5-difluoro-7,9-
dimethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethyl)-2,4-
dimethyl-5-((2-oxo-5-(2,2,2-trifluoroacetamido)indolin-3-ylidene)methyl)-1H-pyrrole-3-
carboxamide (15 mg, 0.021 mmol, 1.0 equiv) in water (5 ml) and MeOH (10 ml) was added 
potassium carbonate (5.8 mg, 0.042 mmol, 2.0 equiv) and the reaction mixture was stirred at 
room temperature for 18 h. Saturated aq. sodium bicarbonate solution (20 ml) and 
dichloromethane (20 ml) were added and the aqueous layer was extracted with dichloromethane 
(2 x 20 ml). The combined organic layers were washed with brine (3 x 50 ml), dried over MgSO4 
and filtered. The solution was cooled to 0°C and acetyl chloride (2.2 µl, 0.0315 mmol, 1.5 equiv) 
and triethylamine (5.8 µl, 0.042 mmol, 2.0 equiv) were added and the reaction mixture was 
stirred for 18 h at room temperature. The reaction was quenched with saturated sodium 
bicarbonate solution (20 ml) and washed with brine (3 x 20 ml). The organic layer was dried 
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over MgSO4 and the solvent was removed. The crude product was purified by silica 
chromatography (dichloromethane/MeOH = 20/1) to give the title compound as a red amorphous 
solid. Yield: 6.5 mg, 0.01 mmol, 48 %. 1H NMR (500 MHz, DMSO-d6) δH (ppm) = 13.62 (s, 
1H), 10.79 (s, 1H), 9.75 (s, 1H), 8.03 (t, J = 5.4 Hz, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.65 (s, 1H), 
7.52 (t, J = 5.3 Hz, 1H), 7.42 (s, 1H), 7.25 (dd, J = 8.3, 2.0 Hz, 1H), 7.05 (d, J = 4.1 Hz, 1H), 
6.81 (d, J = 8.4 Hz, 1H), 6.35 (d, J = 4.1 Hz, 1H), 6.26 (s, 1H), 3.26 (t, J = 5.5 Hz, 2H), 3.10 (t, J 
= 7.7 Hz, 2H), 2.46 (s, 3H), 2.43 (s, 3H), 2.38 (s, 3H), 2.24 (s, 3H), 2.02 (s, 3H). 13C NMR (126 
MHz, DMSO-d6) δC (ppm) = 171.16, 169.51, 167.79, 164.88, 159.11, 157.69, 144.00, 135.90, 
134.47, 133.27, 132.96, 129.14, 128.81, 125.53, 125.39, 125.21, 122.83, 120.21, 118.68, 116.47, 
115.21, 110.70, 109.29, 38.79, 38.51, 33.76, 28.98, 23.95, 23.73, 14.47, 13.30, 10.94, 10.43. MS 
(ESI) m/z = 678.3 [M+Na] +. HPLC (360 nm): tR = 5.597 min (99.8730%). 
Biology 
Stock solutions of inhibitors 
10 mM stock solutions of inhibitors in DMSO were made by dissolving 1 to 5 mg of solid in an 
appropriate amount of DMSO using an ultrasonic water bath (Compounds synthesized; 
Hypothemycin (Abcam); Sunitinib (LC Labs)) or were purchased as 10 mM DMSO Stock 
(Crenolanib, MedChemtronica). 
Cell lines 
Human Leukemia cell lines were purchased at DMSZ (MV4-11: ACC-102; THP-1 ACC-16; 
Jurkat: ACC-282) or provided by K. Stegmaier (NOMO1, U937, MOLM14). Cell lines were 
maintained in RPMI-1640 Medium supplemented with 10% FCS, 2 mM L-glutamine, penicillin 
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(100 U/ml) and streptomycin (100µg/ml) at 37°C at 5% CO2. Cells were maintained at 0.25 to 
1.5 x 106 Cells / ml.  
Cell viability assays 
Fluorescent Endpoint-Assay 
For determining the effect of inhibitors on leukemia cell lines, cells were harvested at densities 
between 0.5 to 1.5 x 106 Cells / ml and subsequently seeded with 25.000 cells / well in a 96 well-
plate in 90 µl of RPMI-1640 medium with 0.1% FCS. After 16 h, cells were treated with vehicle 
or different concentrations of inhibitor (10 µM, 1 µM, 500 nM, 100 nM, 50 nM, 10 nM, 5 nM, 
1 nM) in triplicates and incubated at 37°C at 5% CO2 for 72 h. Viable cells were quantified using 
the Celltiter Blue Assay (Promega) by adding 20 µl of Celltiter Blue reagent and incubation for 
3 h at 37°C. Fluorescence was measured at a Tecan Infinite M1000 microplate reader (Exc. 530 
nm, Em. 560 nm) and the relative inhibition of cell viability was calculated compared to vehicle 
control and cell-free control. Results were plotted to the logarithmic concentration of the 
inhibitor using Prism 7.02 (Graphpad San Diego, CA, USA) and the IC50 is determined using the 
equation “Y=100/(1+10((LogIC50-X)*HillSlope))”. Reported IC50 values are the mean values of two 
independent experiments (Figures S48 – S52). 
Chemiluminescent Endpoint-Assay 
For determining the effect of fluorescent inhibitors on leukemia cell lines, cells were harvested at 
densities between 0.5 to 1.5 x 106 Cells / ml and subsequently seeded with 10.000 cells / well in 
a 384 well-plate in 20 µl of RPMI-1640 medium with 0.1% FCS. After 16 h, cells were treated 
with vehicle or various concentrations of inhibitor (10 µM, 7.5 µM, 5 µM, 2.5 µM, 1 µM, 
500 nM, 100 nM) in triplicates and incubated at 37°C at 5% CO2 for 72 h. 
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Viable Cells were quantified using the Celltiter-Glo 2.0 Assay (Promega) by adding 20 µl of 
Celltiter-Glo reagent to each well at room temperature and cell lysis for 2 min using the shaking 
function of the Tecan M1000 reader. Luminescence was measured after 10 minutes using 500 ms 
integration time and the relative inhibition of cell viability was calculated compared to vehicle 
control and cell-free control. Results were plotted to the logarithmic concentration of the 
inhibitor using Prism 7.02 (Graphpad San Diego, CA, USA) and IC50 is determined using the 
equation “Y=100/(1+10((LogIC50-X)*HillSlope))”. For determination of cytotoxicity in U937, 
MOLM14 and NOMO1 cells, cells were resuspended at 15,000 cells/mL and seeded at 40 µl/ 
well onto 384-well plates.  Cells were then treated with a single agent and analyzed for cell 
viability on day 0 and day 3 post-treatment using the Cell-TiterGlo luminescent assay kit 
(Promega) according to the manufacturer’s protocol.  Luminescence was read on a Fluostar 
Omega Reader (BMG Labtech). 
Chemiluminescent RealTime-Glo MT Cell Viability Assay 
For determining the time-dependent inhibition on FLT3-positive cells, MV4-11 cells were 
harvested at densities between 0.5 to 1.5 x 106 Cells / ml and subsequently seeded with 2.000 
cells / well in a 384 well-plate in 27 µl of RPMI-1640 medium with 0.1% FCS. Cells were 
treated with vehicle or various concentrations of inhibitor (5 µM, 500 nM, 250 nM, 50 nM, 
25 nM, 5 nM, 2.5 nM and 0.5 nM) in triplicates and incubated at 37°C at 5% CO2 for 77 h 
(Figure S39). Viable Cells were quantified using the RealTime-Glo MT Cell Viability Assay 
(Promega) by adding 30 µl of 2-fold reagent mixture to each well. Cell viability was determined 
at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 16 h, 18 h, 20 h, 25 h, 27 h, 29 h, 31 h, 33 h, 35 h, 37 h, 
49 h, 54 h, 57 h and 77 h measuring the luminescence using 500 ms integration time. The 
relative inhibition of cell viability was calculated compared to vehicle control and cell-free 
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control. Results were plotted to the logarithmic concentration of the inhibitor using Prism 7.02 
(Graphpad San Diego, CA, USA) and IC50 is determined for each time-point indicated using the 
equation “Y=100/(1+10((LogIC50-X)*HillSlope))”. 
Western Blot  
Proteins were extracted using Lysis Buffer (Cell Signaling Technology) supplemented with 
Complete, EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics). Protein samples were 
separated by SDS-PAGE and subsequently transferred to PVDF membranes, which were 
blocked in 5% BSA and incubated with primary antibodies against phospho FLT3 (Y969) (Cell 
Signaling Technology Cat. No. 3463), FLT3 (8F2) (Cell Signaling Technology Cat. No. 3462), 
phospho STAT5 (Y694) (Cell Signaling Technology Cat. No. 9351), STAT5 (Cell Signaling 
Technology Cat. No. 9363), GAPDH (Santa Cruz Biotechnology Cat. No. sc-47724). 
Membranes were washed in TBS-T and incubated with the appropriate horseradish peroxidase-
conjugated secondary antibodies.  Signal was detected by enhanced chemi-luminescence 
(ThermoFisher Scientific). 
In-gel digest of FLT3 and MALDI-MS/MS analysis 
2 µg of FLT3 wt diluted in 100 mM phosphate buffer (pH 7.4, total volume 100 µl) were 
incubated with 100 µM of compound for 5 h at 37°C. Samples were freeze-dried and denatured 
in 20 µl of 1x Lämmli buffer for 5 min at 95°C. Samples were purified by SDS gel 
electrophoresis (12% gel). Protein was stained using colloidal coomassie and the gel was 
destained using desalted water. Stained proteins in height of the 73 kDa marker were excised in 
1 mm3 cubes and washed alternatingly in 100 mM ammoniumbicarbonate buffer and acetonitrile 
(200 µl, 4 times each). 100 µl of 10 mM dithiothreitol in ammoniumbicarbonate buffer was 
added and incubated for 25 min at 60°C. The supernatant was discarded, and the gel pieces were 
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washed alternatingly in 100 mM ammoniumbicarbonate buffer and acetonitrile (4 times each). 
100 µl of 10 mM iodoacetamide solution in ammoniumbicarbonate buffer were added and 
incubated at 37°C in the dark for 40 min. The supernatant was discarded, and the gel pieces were 
washed alternatingly in 100 mM ammoniumbicarbonate buffer and acetonitrile (4 times each). 
The gel pieces were rehydrated in 20 µl of 20 ng/µl Trypsin/Lys C mix (Promega) for 10 min, 
then covered with 60 µl 25 mM ammoniumbicarbonate buffer and incubated overnight. 10 µl of 
1% formic acid was added and the supernatant was lyophilized. Samples were reconstituted in 
10 µl of 0.1% trifluoro acetic acid and purified using µ-C18 ZipTip tips (Merck Millipore). 
Samples were spotted in a α-cyano-4-hydroxycinnamic acid matrix and spectra were recorded on 
a Bruker Daltonics autoFlex MALDI TOF spectrometer using positive polarity. Spectra were 
analyzed using Mmass 5. 
Kinase inhibition assays 
Determination of kinase inhibition was performed using the ADP Glo Assay (Promega) or 
determined by external services (Eurofins or DiscoverX) as indicated. 
ADP Glo assay 
The ADP Glo assay was used as described by the supplier. Active kinase was purchased from 
Promega (FLT3-D835Y, 50 ng per assay), Invitrogen (FLT3-ITD, 100 ng per assay) and 
ProQinase (FLT3-wt, 100 ng per assay). Kinase was mixed with 10-fold inhibitor and pre-
incubated for the time indicated at each assay (5 to 30 min). Kinase Reaction Buffer A (4 µl) and 
a mixture (4 µl) of myelobasic protein (MBP, final concentration 0.1 mg/ml) and ATP (final 
concentration 100 µM to 1 mM) was added and the kinase reaction was incubated at room 
temperature for 120 min. ADP Glo reagent (10 µl) was added and incubated for 40 min at room 
temperature. Then, the kinase detection reagent (20 µl) was added and incubated for 30 min 
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(100 µM ATP) to 60 min (1 mM ATP) at room temperature. Relative Inhibition was calculated 
compared to vehicle control and reagent control and were plotted as relative inhibition of kinase 
activity to the logarithmic concentration of the inhibitor using Prism 7.02 (Graphpad, San Diego, 
CA, USA). IC50 is determined using the equation “Y=100/(1+10((LogIC50-X)*HillSlope))”. Ki and kinact 
of compounds 4a and 4b have been determined using the ADP Glo assay with pre-incubation 
times of 2 min, 10 min, 20 min and 30 min. The time-dependent IC50 values were fitted to the 
following equation using nonlinear regression:  
y=(((1+(S/KM))*KI)/(((kinact*(y/((KI*(1+(S/KM)))+y)))*x)/((2-
((kinact*(y/((KI*(1+(S/KM)))+y)))*x))-(2*exp((((-1)*kinact)*(y/((KI*(1+(S/KM)))+y)))*x))))) 
where KI and kinact can be calculated as reported by Krippendorf et al.
42 using GraphPad Prism 
8.0.1. 
Kinase Screening at Eurofins Pharma Drug Discovery Series and DiscoverX 
Kd measurements for 4b were performed using the KINOMEscan® Assay Platform (DiscoverX, 
San Diego, United States). Assays were run using an 11-point 3-fold dilutional series starting at 
30 µM inhibitor. Single-point determination of residual kinase activity for 4b was performed 
using the KinaseProfiler platform (Eurofins, Dundee, United Kingdom). Assays were run using 
10 µM ATP and kinase activity was measured by scintillation. Relative inhibition was calculated 
compared to vehicle control and reagent control. Kinase tree was illustrated using KinMap.36 
Zebrafish Maintenance and Husbandry 
Adult zebrafish wildtype (Danio rerio) are maintained in 60 l fish tanks in a laboratory with no 
daylight and a constant temperature of 28°C. Room light is programmed to a 12 h dark / 12 h 
light cycle. Adult zebrafish are bred in mating containers (2 animals / 1 l) or mating tanks (6 – 8 
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animals / 20 l) that are equipped with plastic grass and a removable sieve at the bottom of the 
tank. Embryos are collected 2 to 3 hours after a light cycle started, rinsed with E3-Medium and 
isolated in petri dishes containing E3-Medium. Living embryos were sorted randomly 24 hours 
past fertilization in 96 well plates (n=1 / Well) or 24 Well plate (n = 10 / Well). Fish keeping 
protocols are approved by the Darmstadt administrative authority and documented. All fish were 
treated humanely. 
Danio rerio Toxicity Assay 
Stock solutions (10 mM in DMSO) of test compounds are diluted to 10x final concentrations. 
Embryos are sorted in 180 µl of E3 Medium and 24 hpf test compounds are added to give the 
final 1x concentrations. Survival was monitored every 24 h by observation of heart-beat. 
Embryos were euthanized 120 h past fertilization using eugenol. Survival rates were calculated 
compared to 0.1 % DMSO-treated controls and fish water controls. Images were recorded using 
a Panasonic Lumix GX8 equipped with a Lumix G macro 1:2.8/30 ASPH objective and a 10 mm 
and 16 mm extension tube (Meike MK-P-AF3B). Fluorescence was recorded using an 
AxioScopeA.1 microscope (Zeiss) equipped with an Axiocam MRc or equipped with a Nuance 
FX multispectral imaging system. 
Determination of compound half-life time 
Inhibitor half-life has been determined using 1.5 ml HPLC vials injecting 20 µl per run using the 
HPLC method as described above. All buffers are sonicated for 30 min in an open flask and have 
been purged with argon for 6 hours. 5 µl of a 1 mM DMSO Stock solution of inhibitor was 
mixed with 45 µl of acetonitrile, 50 µl of a 10 mM solution of nucleophile in 100 mM potassium 
phosphate buffer at the pH value indicated and 400 µl of 100 mM potassium phosphate buffer 
under argon immediately before the first injection into the HPLC. The samples have been 
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measured at t = 0 min, 34 min, 68 min, 102 min, 136 min, 170 min, 204 min. The area of the 
signal corresponding to the inhibitor was determined (mAU·s) and the relative area compared to 
the first measurement was plotted to the corresponding time-point. The half-life was determined 
using one-phase exponential decay fit of Graphpad Prism 7.02 (Y = (Y0 - Plateau)·exp
(-K*X) + 
Plateau). Half-life is calculated as t1/2 = ln (2) / k. 
Detection of fluorescence using SDS-PAGE and subsequent Western blotting 
500 ng FLT3-D835Y (Promega, 10 µl) is diluted in 100 mM phosphate buffer (pH 7.4, total 
volume 100 µl) and is incubated with 100 µM of compound for 3 h at 37°C. Then 1 µl of 100-
fold DMSO stock of the fluorophore is added (final concentration 1 µM) and incubated for 2 h at 
37°C. Samples were freeze-dried and reconstituted with 10 µl of a 10 mM solution of GSH and 
incubated for 2 h at 37°C. Then the samples are denatured by adding 10 µl of 2x Lämmli buffer 
and incubation for 5 min at 95°C. Samples are subjected to SDS gel electrophoresis (12% gel) 
and subsequently blotted to a PVDF membrane using constant ampere (2 mA / cm2 gel, 45 min) 
and Western blot buffer (48 mM Tris, 39 mM glycine, 10% methanol). The blotting membrane 
was washed with water twice and dried in an air flow for 30 min. Fluorescence was recorded 
using a Vilber Fusion FX7 Edge imaging system using the settings indicated in the 
corresponding image. 
 
ASSOCIATED CONTENT 
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charge via the Internet at http://pubs.acs.org. 
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